Lyme disease RNA vaccine
An mRNA-based Lyme disease vaccine formulated in lipid nanoparticles addresses the challenge of varying OspA serotypes by inducing a potent immune response, effectively protecting against Lyme disease.
Patent Information
- Application Number
- CN202280090665.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2021-12-23
- Filing Date
- 2022-12-16
- Publication Date
- 2024-12-06
AI Technical Summary
There is a need for an effective RNA-based vaccine against Lyme disease that induces a strong immune response to neutralize the infection, as existing vaccines are lacking and the OspA serotypes vary by geographic region, complicating vaccine development.
A Lyme disease vaccine comprising mRNA encoding Borrelia-derived antigenic polypeptides, particularly OspA, formulated in lipid nanoparticles (LNPs) with specific lipid ratios and chemical modifications, to elicit a humoral immune response.
The vaccine effectively induces a robust immune response, including higher serum concentrations of anti-OspA antibodies, providing protection against Lyme disease across different OspA serotypes.
Smart Images

Figure BDA0004972018600000041 
Figure BDA0004972018600000051 
Figure BDA0004972018600000141
Abstract
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is related to EP priority application number 21315283.8 filed on December 17, 2021 and EP priority application number 21315291.1 filed on December 23, 2021, the contents of each of which are incorporated herein by reference in their entirety for all purposes. Background Art
[0002] Lyme borreliosis (that is, Lyme disease) is a kind of zoonotic disease caused by some bacterial species in Borrelia (Borrelia), and is transmitted to people and other mammals by the bite of the hard tick species (Ixodes spp.) ticks infected.Lyme disease is a global public health problem, and cases have been reported in the temperate climate zones across Europe, North America and Asia.Outer surface protein A (OspA) is an abundant Borrelia immunogenic lipoprotein.Found in Borrelia at least seven different OspA serotypes (serotype 1-7), and there are different Borrelia gene species that may cause Lyme borreliosis worldwide.In addition, the locality scope of the ticks carrying Borrelia means that the OspA serotype related to the Lyme disease of the patient in a geographic region may be unrelated to the Lyme disease of the patient in another geographic region.
[0003] RNA-based vaccines (e.g., mRNA vaccines) have recently emerged as another type of vaccine with a rapid, safe, and cost-effective production process, particularly for viral pathogens. mRNA vaccines for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) primarily use spike viral proteins as antigens. Typically combined with a delivery vehicle such as lipid nanoparticles (LNPs), COVID-19 mRNA vaccines can achieve high efficacy. Due to the lack of available effective Lyme disease vaccines, there is a need for RNA-based Lyme disease vaccines that induce a strong immune response to potently neutralize Lyme disease infection. Summary of the invention
[0004] In one aspect, the present disclosure provides a Lyme disease vaccine comprising a messenger RNA (mRNA) comprising an open reading frame (ORF) encoding at least one antigenic polypeptide derived from at least one Borrelia bacterium.
[0005] In certain embodiments, at least one bacterium is selected from the species B. burgdorferi, B. afzelii, B. garinii, B. bavariensis, B. mayonii, B. spielmanii, B. lusitaniae, B. bissettii, and / or B. valaisiana, or any strain or isolate thereof.
[0006] In certain embodiments, the at least one antigenic polypeptide comprises at least one Borrelia lipoprotein.
[0007] In certain embodiments, the at least one lipoprotein is OspA or a fragment or variant thereof.Preferably, the fragment or variant comprises at least 5 amino acids.
[0008] In certain embodiments, the at least one OspA is derived from OspA serotype (ST) 1, 2, 3, 4, 5, 6 and / or 7.
[0009] In certain embodiments, the at least one OspA serotype 1-7 is from serotype 1 Borrelia burgdorferi strain B31, serotype 2 Borrelia afzawa strain PKO, serotype 3 Borrelia garinii strain PBr, serotype 4 Borrelia bavariae, serotype 5 Borrelia garinii, serotype 6 Borrelia garinii, or serotype 7 Borrelia garinii.
[0010] In certain embodiments, the at least one OspA polypeptide comprises an amino acid sequence that is at least 85% identical to any one of SEQ ID NOs: 1-7.
[0011] In certain embodiments, the mRNA of a Lyme disease vaccine disclosed herein comprises a nucleotide sequence that is at least 85% identical to any one of SEQ ID NOs: 10-13 and 16-19.
[0012] In certain embodiments, the mRNA of the Lyme disease vaccine disclosed herein encodes at least two different OspA serotypes or fragments or variants thereof. Preferably, each fragment or variant comprises at least 5 amino acids.
[0013] In certain embodiments, OspA, or a fragment or variant thereof, of one serotype is fused to OspA, or a fragment or variant thereof, of a different serotype.
[0014] In certain embodiments, the fused OspA or fragments or variants thereof of different serotypes are separated by a linker sequence.
[0015] In certain embodiments, the linker sequence is derived from P66.
[0016] In certain embodiments, the linker sequence comprises an amino acid sequence that is at least 85% identical to SEQ ID NO:8.
[0017] In certain embodiments, the linker sequence comprises an amino acid sequence that is at least 85% identical to SEQ ID NO:9.
[0018] In certain embodiments, the mRNA is a non-replicating mRNA.
[0019] In certain embodiments, the mRNA is a self-replicating mRNA or a trans-replicating mRNA.
[0020] In certain embodiments, the mRNA comprises at least one chemical modification.
[0021] In certain embodiments, the chemical modification is selected from the group consisting of pseudouridine, N1-methylpseudouridine, 2-thiouridine, 4'-thiouridine, 5-methylcytidine, 2-thiol-1-methyl-1-deaza-pseudouridine, 2-thiol-1-methyl-pseudouridine, 2-thiol-5-aza-uridine, 2-thiol-dihydropseudouridine, 2-thiol-dihydrouridine, 2-thiol-pseudouridine, 4-methoxy-2-thiol-pseudouridine, 4-methoxy-pseudouridine, 4-thiol-1-methyl-pseudouridine, 4-thiol-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methyluridine, 5-methyluridine, and 2'-O-methyluridine.
[0022] In certain embodiments, the chemical modification is selected from the group consisting of pseudouridine, N1-methylpseudouridine, 5-methylcytidine, 5-methoxyuridine, and combinations thereof. In certain embodiments, the chemical modification is N1-methylpseudouridine.
[0023] In certain embodiments, the mRNA is formulated in a non-viral delivery system.
[0024] In certain embodiments, the mRNA is formulated in lipid nanoparticles (LNPs).
[0025] In certain embodiments, the LNP comprises at least one cationic lipid.
[0026] In certain embodiments, the cationic lipid is biodegradable. In certain embodiments, the cationic lipid is not biodegradable.
[0027] In certain embodiments, the cationic lipid is cleavable. In certain embodiments, the cationic lipid is not cleavable.
[0028] In certain embodiments, the cationic lipid is selected from the group consisting of: ML7 / OF-02; cKK-E10; GL-HEPES-E3-E10-DS-3-E18-1; GL-HEPES-E3-E12-DS-4-E10; GL-HEPES-E3-E12-DS-3-E14; 9-heptadecyl 8-{(2-hydroxyethyl)[6-oxo-6-(undecanyloxy)hexyl]amino}octanoate (SM-102); and (4-hydroxybutyl)azanediyl]bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315).
[0029] In certain embodiments, the cationic lipid is cKK-E10.
[0030] In certain embodiments, the LNP further comprises a polyethylene glycol (PEG)-conjugated (PEGylated) lipid, a cholesterol-based lipid, and a helper lipid.
[0031] In certain embodiments, the LNP comprises: a cationic lipid at a molar ratio between 35% and 55%, a polyethylene glycol (PEG)-conjugated (PEGylated) lipid at a molar ratio between 0.25% and 2.75%, a cholesterol-based lipid at a molar ratio between 20% and 45%, and an auxiliary lipid at a molar ratio between 5% and 35%, wherein all molar ratios are relative to the total lipid content of the LNP.
[0032] In certain embodiments, the LNP comprises: a cationic lipid at a molar ratio of 40%, a PEGylated lipid at a molar ratio of 1.5%, a cholesterol-based lipid at a molar ratio of 28.5%, and a helper lipid at a molar ratio of 30%.
[0033] In certain embodiments, the PEGylated lipid is dimyristoyl-PEG2000 (DMG-PEG2000) or 2-[(polyethylene glycol)-2000]-N,N-ditetradecanoylacetamide (ALC-0159).
[0034] In certain embodiments, the cholesterol-based lipid is cholesterol.
[0035] In certain embodiments, the helper lipid is 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) or 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC).
[0036] In some embodiments, the LNP comprises: 40% by molar ratio of cKK-E10, 1.5% by molar ratio of DMG-PEG2000, 28.5% by molar ratio of cholesterol, and 30% by molar ratio of DOPE.
[0037] In certain embodiments, the average diameter of the LNPs is 30-200 nm. In certain embodiments, the average diameter of the LNPs is 80-150 nm.
[0038] In certain embodiments, the mRNA of a Lyme disease vaccine disclosed herein comprises at least one 5' untranslated region (5'UTR), at least one 3' untranslated region (3'UTR), and at least one polyadenylation (poly A) sequence.
[0039] In certain embodiments, the mRNA comprises at least the following structural elements: (i) a 5' cap having the following structure: (ii) a 5' untranslated region (5'UTR) having the nucleic acid sequence of SEQ ID NO: 14; (iii) at least one OspA open reading frame having the nucleic acid sequence of any one of SEQ ID NOs: 16-19; (iv) a 3' untranslated region (3'UTR) having the nucleic acid sequence of SEQ ID NO: 15; and (v) Poly A tail.
[0040] In one aspect, the disclosure provides a Lyme disease vaccine comprising a messenger RNA (mRNA) comprising an open reading frame (ORF) encoding at least one antigenic polypeptide derived from at least one Borrelia bacterium, wherein the mRNA comprises at least the following structural elements: (i) a 5' cap having the following structure: (ii) a 5' untranslated region (5'UTR) having the nucleic acid sequence of SEQ ID NO: 14; (iii) at least one OspA open reading frame having the nucleic acid sequence of any one of SEQ ID NOs: 16-19; (iv) a 3' untranslated region (3'UTR) having the nucleic acid sequence of SEQ ID NO: 15; and (v) poly A tail; The mRNA is formulated in lipid nanoparticles (LNPs), which contain: cKK-E10 with a molar ratio of 40%, DMG-PEG2000 with a molar ratio of 1.5%, cholesterol with a molar ratio of 28.5%, and DOPE with a molar ratio of 30%.
[0041] In another aspect, the Lyme disease vaccines disclosed herein are used to elicit an immune response, preferably a humoral immune response, and / or to treat or prevent Lyme disease in a subject in need thereof.
[0042] In another aspect, the present disclosure provides a method of eliciting an immune response, preferably a humoral immune response, and / or treating or preventing Lyme disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a Lyme disease vaccine disclosed herein, optionally intramuscularly, intranasally, intravenously, subcutaneously, or intradermally.
[0043] In another aspect, the present disclosure provides use of a Lyme disease vaccine disclosed herein for the manufacture of a medicament for eliciting an immune response, preferably a humoral immune response, and / or treating or preventing Lyme disease in a subject in need thereof.
[0044] In certain embodiments, the subject has a higher serum concentration of anti-OspA antibodies after administration of the Lyme disease vaccine relative to a subject administered a Lyme disease vaccine comprising an OspA recombinant protein vaccine.
[0045] In certain embodiments, the subject is a mammal, optionally a human, dog, cat, llama, cow, sheep, goat, horse, rodent, mouse, rat, rabbit, monkey, primate or pig. In certain exemplary embodiments, the subject is a human. BRIEF DESCRIPTION OF THE DRAWINGS
[0046] The foregoing and other features and advantages of the present disclosure will be more fully understood from the following detailed description of illustrative embodiments taken in conjunction with the accompanying drawings.
[0047] Figure 1A-1B Depicted are the results of the anti-OspA ST1 IgG ELISA in mice after the first dose (day 20) ( Figure 1A ) and after the second dose (day 35) ( Figure 1B ) IgG titer values. Dashed line = limit of quantitation.
[0048] Figure 2A-2B Depicted are the results of the anti-OspA ST2 IgG ELISA in mice after the first dose (day 20) ( Figure 2A ) and after the second dose (day 35) ( Figure 2B ) IgG titer values. Dashed line = limit of quantitation. DETAILED DESCRIPTION
[0049] The present disclosure particularly relates to novel RNA (e.g., mRNA) compositions of the antigenic polypeptides (e.g., OspA albumen) derived from Borrelia and the method for vaccination therewith. In particular, the present disclosure relates to the mRNA of the coding OspA albumen formulated in a non-viral delivery system, particularly lipid nanoparticles (LNP). I. Definitions
[0050] Unless otherwise defined herein, the scientific and technical terms used in conjunction with this disclosure should have the meaning commonly understood by those of ordinary skill in the art. Although methods and materials similar to or equivalent to those described herein can also be used in the practice or test of this disclosure, exemplary methods and materials are described below. In the event of a conflict, this specification including the definition shall prevail. Usually, the nomenclature and technology used in conjunction with cell and tissue culture, molecular biology, virology, immunology, microbiology, genetics, analytical chemistry, synthetic organic chemistry, medicine and pharmaceutical chemistry, and protein and nucleic acid chemistry and hybridization as described herein are those nomenclatures and technologies well known and commonly used in the art. Enzymatic reactions and purification techniques are carried out as usually realized in this area or as described herein according to the manufacturer's instructions. Further, unless the context requires otherwise, singular terms should include plural numbers, and plural terms should include singular numbers. Throughout the present specification and examples, the words "have" and "comprise" or variations such as "has / having", "comprises / comprising" should be understood to mean the inclusion of the stated integer or groups of integers but not the exclusion of any other integer or groups of integers. All publications and other references mentioned herein are incorporated by reference in their entirety. Although a number of documents are cited herein, this citation does not constitute an admission that any of these documents forms part of the common general knowledge in the art.
[0051] It should be noted that "a / an" entity refers to one or more of the entity; for example, "a / an nucleotide sequence" is understood to mean one or more nucleotide sequences. Therefore, the terms "a / an", "one or more", and "at least one" can be used interchangeably herein.
[0052] In addition, the use of "and / or" herein should be understood as explicitly disclosing each of the two specified features or components with or without the other. Thus, the term "and / or" as used in phrases such as "A and / or B" herein is intended to include "A and B," "A or B," "A" (alone), and "B" (alone). Similarly, the term "and / or" as used in phrases such as "A, B, and / or C" is intended to cover each of the following: A, B, and C; A, B or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).
[0053] It should be understood that anywhere aspects are described herein with the language "comprising," similar aspects described in the form of "consisting of" and / or "consisting essentially of" are also provided.
[0054] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the present disclosure relates. For example, Concise Dictionary of Biomedicine and Molecular Biology, Juo, Pei-Show, 2nd edition, 2002, CRC Press; The Dictionary Of Cell And Molecular Biology, 3rd edition, 1999, Academic Press; and Oxford Dictionary Of Biochemistry And Molecular Biology, Revised edition, 2000, Oxford University Press can provide a general dictionary of many of the terms used in the present disclosure for one of ordinary skill.
[0055] Units, prefixes and symbols are all expressed in a form acceptable to the International System of Units (SI). Numerical ranges include numbers that define the range. Unless otherwise indicated, amino acid sequences are written from left to right in the direction of amino to carboxyl. The headings provided herein are not limitations on the various aspects of the disclosure. Therefore, the terms defined immediately below can be more fully defined by reference to the specification as a whole.
[0056] The term "approximately" or "about" is used herein to mean approximately, roughly, approximately, or about. When the term "approximately" is used in conjunction with a numerical range, it defines the range by extending the boundaries above and below the numerical values described. In general, the term "approximately" can define a numerical value to be above and below a specified value with a change of, for example, 10% up and down (higher or lower). In some embodiments, the term indicates a deviation of ±10%, ±5%, ±4%, ±3%, ±2%, ±1%, ±0.9%, ±0.8%, ±0.7%, ±0.6%, ±0.5%, ±0.4%, ±0.3%, ±0.2%, ±0.1%, ±0.05% or ±0.01%. In some embodiments, "approximately" indicates a deviation of ±10% from the indicated numerical value. In some embodiments, "approximately" indicates a deviation of ±5% from the indicated numerical value. In some embodiments, "approximately" indicates a deviation of ±4% from the indicated numerical value. In some embodiments, "approximately" indicates a deviation of ±3% from the indicated numerical value. In some embodiments, "approximately" indicates a deviation of ±2% from the indicated numerical value. In some embodiments, "about" indicates a deviation from the indicated value of ±1%. In some embodiments, "about" indicates a deviation from the indicated value of ±0.9%. In some embodiments, "about" indicates a deviation from the indicated value of ±0.8%. In some embodiments, "about" indicates a deviation from the indicated value of ±0.7%. In some embodiments, "about" indicates a deviation from the indicated value of ±0.6%. In some embodiments, "about" indicates a deviation from the indicated value of ±0.5%. In some embodiments, "about" indicates a deviation from the indicated value of ±0.4%. In some embodiments, "about" indicates a deviation from the indicated value of ±0.3%. In some embodiments, "about" indicates a deviation from the indicated value of ±0.1%. In some embodiments, "about" indicates a deviation from the indicated value of ±0.05%. In some embodiments, "about" indicates a deviation from the indicated value of ±0.01%.
[0057] As used herein, the term "messenger RNA" or "mRNA" refers to a polynucleotide encoding at least one polypeptide. As used herein, mRNA encompasses both modified RNA and unmodified RNA. mRNA may contain one or more coding regions and non-coding regions. The coding region may alternatively be referred to as an open reading frame (ORF). The non-coding region in mRNA includes a 5' cap, a 5' untranslated region (UTR), a 3' UTR, and a poly A tail. mRNA can be purified from natural sources, produced using a recombinant expression system (e.g., in vitro transcription) and optionally purified, or chemically synthesized.
[0058] As used herein, the term "open reading frame," "ORF," or "coding region" refers to a polynucleotide sequence that begins with a start codon (e.g., ATG) and ends with a stop codon (e.g., TAA, TAG, or TGA) without any other stop codons in between, and encodes a protein (e.g., an antigenic polypeptide derived from a Borrelia bacterium).
[0059] The disclosure also includes fragments or variants of polypeptides, and any combination thereof.When referring to the OspA polypeptide molecules disclosed herein, the term "fragment" or "variant" includes any polypeptide retaining at least some properties of the reference polypeptide (for example, the specific antigenic properties of the polypeptide or the ability of the polypeptide to help induce antibody binding).The fragment of the polypeptide includes a fragment of N-terminal and / or C-terminal truncation, such as C-terminal fragment and N-terminal fragment, and a deletion fragment, but does not include naturally occurring full-length polypeptides (or mature polypeptides).A deletion fragment refers to a polypeptide lacking 1 or more internal amino acids from a full-length polypeptide.The variant of the polypeptide includes a fragment as described above, and a polypeptide having an amino acid sequence that has been changed due to amino acid substitution, deletion or insertion.Variant can be naturally occurring or non-naturally occurring.Can use mutagenesis techniques known in the art to produce non-naturally occurring variants.Variant polypeptides can include conservative or non-conservative amino acid substitutions, deletions or additions.Such a variation (that is, truncation and / or amino acid substitutions, deletions or insertions) can occur at the amino acid level, or correspondingly at the nucleic acid level.
[0060] "Conservative amino acid substitution" is a substitution in which an amino acid residue is replaced by an amino acid residue with a similar side chain. Families of amino acid residues with similar side chains have been defined in the art, including basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), non-polar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Therefore, if an amino acid in a polypeptide is replaced by another amino acid from the same side chain family, the substitution is considered to be conservative. In another embodiment, an amino acid string can be conservatively replaced with a structurally similar string that is different in the order and / or composition of the side chain family members.
[0061] As used herein, the term "connection" refers to a first amino acid sequence or nucleotide sequence being covalently or non-covalently connected to a second amino acid sequence or nucleotide sequence, respectively. The first amino acid sequence or nucleotide sequence may be directly connected or connected in parallel to the second amino acid sequence or nucleotide sequence, or alternatively, the insertion sequence may covalently connect the first sequence to the second sequence. The term "connection" not only means the fusion of the first amino acid sequence with the second amino acid sequence at the C-terminus or N-terminus, but also includes inserting the entire first amino acid sequence (or the second amino acid sequence) into any two amino acids in the second amino acid sequence (or the first amino acid sequence, respectively). In one embodiment, the first amino acid sequence may be connected to the second amino acid sequence by a peptide bond or a joint. The first nucleotide sequence may be connected to the second nucleotide sequence by a phosphodiester bond or a joint. The joint may be a peptide or polypeptide (for a polypeptide chain) or a nucleotide or nucleotide chain (for a nucleotide chain) or any chemical moiety (for both polypeptide and polynucleotide chains). The term "connection" is also represented by a hyphen (-).
[0062] As used herein, the term "immune response" refers to the response of cells of the immune system (such as B cells, T cells, dendritic cells, macrophages or polymorphonuclear cells) to a stimulus (such as an antigen or vaccine). The immune response can include any cell of the body that participates in the host defense response, including, for example, epithelial cells that secrete interferons or cytokines. The immune response includes, but is not limited to, innate and / or adaptive immune responses.
[0063] As used herein, "protective immune response" refers to an immune response that protects a subject from infection (e.g., preventing infection or preventing the occurrence of a disease associated with infection). Methods for measuring immune responses are well known in the art and include, for example, by measuring the proliferation and / or activity of lymphocytes (e.g., B cells or T cells), the secretion of cytokines or chemokines, inflammation, antibody production, etc.
[0064] As used herein, an "antibody response" is an immune response that produces antibodies.
[0065] As used herein, "antigen" refers to a factor that triggers an immune response; and / or a factor that is bound by a T cell receptor when exposed or administered to an organism (e.g., when presented by an MHC molecule) or a factor that is bound to an antibody (e.g., produced by a B cell). In some embodiments, an antigen triggers a humoral response in an organism (e.g., including the production of antigen-specific antibodies). Alternatively or in addition, in some embodiments, an antigen triggers a cellular response in an organism (e.g., involving a T cell whose receptor specifically interacts with the antigen). A specific antigen can trigger an immune response in one or several members of a target organism (e.g., mouse, rabbit, primate, human), but cannot trigger an immune response in all members of the target organism species. In certain embodiments, antigen causes immune response in at least about 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% member of target organism species.In certain embodiments, antigen is combined with antibody and / or t cell receptor, and may induce or may not induce specific physiological response in organism.In certain embodiments, for example, antigen can be combined with antibody and / or t cell receptor in vitro, no matter whether this interaction occurs in vivo.In certain embodiments, antigen reacts with the product of specific body fluid or cellular immunity.Antigen comprises the OspA polypeptide (for example, OspA ST1 and OspA ST2) encoded by mRNA as described herein.
[0066] As used herein, "adjuvant" refers to a substance or vehicle that enhances the immune response to an antigen. An adjuvant may include, but is not limited to, a suspension of a mineral (e.g., alum, aluminum hydroxide, or phosphate) on which an antigen is adsorbed; an oil-in-water or water-in-oil emulsion (e.g., Freund's incomplete adjuvant) emulsified in mineral oil or water. Killed mycobacteria (e.g., Freund's complete adjuvant) are sometimes included to further enhance antigenicity. Immunostimulatory oligonucleotides (e.g., CpG motifs) may also be used as adjuvants (e.g., see U.S. Patent Nos. 6,194,388; 6,207,646; 6,214,806; 6,218,371; 6,239,116; 6,339,068; 6,406,705; and 6,429,199). Adjuvants may also include biomolecules, such as Toll-like receptor (TLR) agonists and co-stimulatory molecules.
[0067] As used herein, "antigenic OspA polypeptide" refers to a polypeptide comprising all or part of an OspA amino acid sequence that is long enough to render the molecule antigenic with respect to Lyme disease and an OspA polypeptide.
[0068] As used herein, "subject" refers to any member of the animal kingdom. In some embodiments, "subject" refers to a human. In some embodiments, "subject" refers to a non-human animal. In certain embodiments, the non-human subject is a mammal (e.g., a rodent, mouse, rat, rabbit, monkey, llama, horse, dog, cat, cow, sheep, goat, primate, or pig). In some embodiments, where the subject is a human, the terms "individual" or "patient" are used and are intended to be interchangeable with "subject."
[0069] As used herein, the terms "prevent", "preventing", "prevention", "prophylaxis" (and grammatical variations thereof) refer to partially or completely inhibiting the onset of one or more symptoms or characteristics of a particular infection, disease, disorder, and / or condition.
[0070] As used herein, the terms "treat", "treating", "treatment", "therapy", "therapeutic" (and grammatical variations thereof) refer to partially or completely alleviating, ameliorating, improving, alleviating, inhibiting the progression of, and / or reducing the severity of, one or more symptoms or characteristics of an infection, disease, disorder, and / or condition.
[0071] As used herein, the term "effective amount" refers to an amount (e.g., an amount of a nucleic acid or composition) sufficient to achieve a beneficial or desired result. An effective amount can be administered in one or more administration regimens, applications or dosages, and is not intended to be limited to a specific formulation or route of administration.
[0072] The term "effective amount" includes, for example, a "therapeutically effective amount" and / or a "prophylactically effective amount".
[0073] As used herein, the phrase "therapeutically effective amount" refers to an amount (e.g., an amount of a nucleic acid or composition) effective to produce some desired therapeutic effect in treating infections, diseases, disorders and / or conditions at a reasonable benefit / risk ratio applicable to any medical treatment.
[0074] As used herein, the phrase "prophylactically effective amount" refers to an amount (e.g., an amount of a nucleic acid or composition) effective to produce some desired prophylactic effect in preventing infection, disease, disorder and / or condition at a reasonable benefit / risk ratio applicable to any medical treatment.
[0075] As used herein, the term "vaccination" or "vaccinate" refers to the administration of a composition intended to generate an immune response, for example, to a pathogenic agent. Vaccination can be administered before, during, and / or after exposure to the pathogenic agent and / or the onset of one or more symptoms, and in some embodiments, before, during, and / or shortly after exposure to the pathogenic agent. In some embodiments, vaccination comprises multiple administrations of a vaccine composition at appropriate intervals.
[0076] The present disclosure describes nucleic acid sequences (eg, DNA sequences and RNA sequences) and amino acid sequences that have a certain degree of identity to a given nucleic acid sequence or amino acid sequence (reference sequence), respectively.
[0077] The "sequence identity" between two nucleic acid sequences indicates the percentage of identical nucleotides between the sequences. The "sequence identity" between two amino acid sequences indicates the percentage of identical amino acids between the sequences.
[0078] The terms "% identical", "% identity" or similar terms are intended to refer in particular to the percentage of identical nucleotides or amino acids in an optimal alignment between the sequences to be compared. The percentages are purely statistical, and the differences between the two sequences may, but are not necessarily, randomly distributed over the entire length of the sequences to be compared. The comparison of two sequences is usually performed in the following manner: after optimal alignment, the sequences are compared with respect to segments or "comparison windows" to identify local regions of corresponding sequences. Optimal alignment for comparison can be performed manually or with the aid of the local homology algorithm of Smith and Waterman, 1981, Ads App. Math. 2, 482, with the aid of the local homology algorithm of Needleman and Wunsch, 1970, J. Mol. Biol. 48, 443, with the aid of the similarity search algorithm of Pearson and Lipman, 1988, Proc. Natl Acad. Sci. USA 88, 2444, or with the aid of computer programs that use such algorithms (e.g., GAP, BESTFIT, FASTA, BLAST P, BLAST N, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Drive, Madison, Wis.).
[0079] The percent identity is obtained by determining the number of corresponding identical positions in the sequences being compared, dividing this number by the number of compared positions (eg, the number of positions in the reference sequence), and multiplying this result by 100.
[0080] In some embodiments, the degree of identity given for a region is at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or about 100% of the entire length of the reference sequence. For example, if the reference nucleic acid sequence consists of 200 nucleotides, the degree of identity is given for at least about 100, at least about 120, at least about 140, at least about 160, at least about 180, or about 200 nucleotides (contiguous nucleotides in some embodiments). In some embodiments, the degree of identity is given for the entire length of the reference sequence.
[0081] A nucleic acid sequence or amino acid sequence having a specific degree of identity to a given nucleic acid sequence or amino acid sequence, respectively, can have at least one functional property of the given sequence, for example and in some cases, is functionally equivalent to the given sequence. In some embodiments, a nucleic acid sequence or amino acid sequence having a specific degree of identity to a given nucleic acid sequence or amino acid sequence is functionally equivalent to the given sequence.
[0082] As used herein, the term "kit" refers to a packaged set of related components, such as one or more compounds or compositions and one or more related materials, such as solvents, solutions, buffers, instructions, or desiccants. II. RNA
[0083] The Lyme disease vaccine of this disclosure comprises at least one ribonucleic acid (RNA), and this ribonucleic acid comprises the ORF of the antigenic polypeptide (such as OspA protein antigen (for example, OspA ST1 or OspA ST2)) that encodes to be derived from Borrelia.In certain embodiments, RNA is messenger RNA (mRNA), and this messenger mRNA comprises the open reading frame of encoding OspA protein antigen.In certain embodiments, RNA (for example, mRNA) further comprises at least one 5'UTR, 3'UTR, poly A tail and / or 5' cap. II.A.5' cap
[0084] The mRNA 5' cap can provide resistance to nucleases found in most eukaryotic cells and promote translation efficiency. Several types of 5' caps are known. The 7-methylguanosine cap (also called the "m 7 G" or "cap-0") comprises a guanosine linked to the first transcribed nucleotide via a 5'-5'-triphosphate bond.
[0085] The 5' cap is typically added as follows: first, an RNA terminal phosphatase removes one terminal phosphate group from the 5' nucleotide, leaving two terminal phosphates; guanosine triphosphate (GTP) is then added to the terminal phosphate via a guanylate transferase, resulting in a 5'5'5 triphosphate linkage; then, the 7-nitrogen of guanine is methylated by a methyltransferase. Examples of cap structures include, but are not limited to, m7G(5')ppp, (5'(A, G(5')ppp(5')A, and G(5')ppp(5')G. Additional cap structures are described in U.S. Publication No. US 2016 / 0032356 and U.S. Publication No. US2018 / 0125989, which are incorporated herein by reference.
[0086] 5' capping of polynucleotides can be concomitantly accomplished during an in vitro transcription reaction using the following chemical RNA cap analogs according to the manufacturer's protocol to generate a 5'-guanosine cap structure: 3'-O-Me-m7G(5')ppp(5')G(ARCA cap); G(5')ppp(5')A; G(5')ppp(5')G; m7G(5')ppp(5')A; m7G(5')ppp(5')G; m7G(5')ppp(5')(2'OMeA)pG; m7G(5')ppp(5')(2'OMeA)pU; m7G(5')ppp(5')(2'OMeG)pG (New England BioLabs, Ipswich, MA; TriLink Biotechnologies). 5'-capping of the modified RNA can be accomplished post-transcriptionally using a vaccinia virus capping enzyme to generate the Cap 0 structure: m7G(5')ppp(5')G. The Cap 1 structure can be generated using both a vaccinia virus capping enzyme and a 2'-O methyltransferase to generate: m7G(5')ppp(5')G-2'-O-methyl. The Cap 2 structure can be generated from the Cap 1 structure and then the 5' third to last nucleotide is 2'-O-methylated using a 2'-O methyl-transferase. The Cap 3 structure can be generated from the Cap 2 structure and then the 5' fourth to last nucleotide is 2'-O-methylated using a 2'-O methyl-transferase.
[0087] In certain embodiments, the mRNA of the present disclosure comprises a 5' cap selected from the group consisting of: 3'-O-Me-m7G(5')ppp(5')G (ARCA cap), G(5')ppp(5')A, G(5')ppp(5')G, m7G(5')ppp(5')A, m7G(5')ppp(5')G, m7G(5')ppp(5')(2'OMeA)pG, m7G(5')ppp(5')(2'OMeA)pU, and m7G(5')ppp(5')(2'OMeG)pG.
[0088] In certain embodiments, the mRNA of the present disclosure comprises a 5' cap: II.B. Untranslated Region (UTR)
[0089] In some embodiments, the mRNA of the present disclosure includes a 5' and / or 3' untranslated region (UTR). In the mRNA, the 5'UTR starts at the transcription start site and continues to the start codon, but does not include the start codon. The 3'UTR starts immediately after the stop codon and continues until the transcription termination signal.
[0090] In some embodiments, the mRNA disclosed herein comprises a 5'UTR comprising one or more elements that affect mRNA stability or translation. In some embodiments, the length of the 5'UTR can be about 10 to 5,000 nucleotides. In some embodiments, the length of the 5'UTR can be about 50 to 500 nucleotides. In some embodiments, the length of the 5'UTR is at least about 10 nucleotides, about 20 nucleotides, about 30 nucleotides, about 40 nucleotides, about 50 nucleotides, about 100 nucleotides, about 150 nucleotides, about 200 nucleotides, about 250 nucleotides, about 300 nucleotides, about 350 nucleotides, about 400 nucleotides, about 450 nucleotides, about 500 nucleotides, about 550 nucleotides, about 600 nucleotides, about 700 nucleotides, about 800 nucleotides, about 900 nucleotides, about 1000 nucleotides, about 15 ... about 650 nucleotides in length, about 700 nucleotides in length, about 750 nucleotides in length, about 800 nucleotides in length, about 850 nucleotides in length, about 900 nucleotides in length, about 950 nucleotides in length, about 1,000 nucleotides in length, about 1,500 nucleotides in length, about 2,000 nucleotides in length, about 2,500 nucleotides in length, about 3,000 nucleotides in length, about 3,500 nucleotides in length, about 4,000 nucleotides in length, about 4,500 nucleotides in length or about 5,000 nucleotides in length.
[0091] In some embodiments, the mRNA disclosed herein comprises a 3'UTR comprising one or more of the following: a polyadenylation signal, a binding site for a protein that affects the stability of the position of the mRNA in the cell, or one or more binding sites for a miRNA. In some embodiments, the length of the 3'UTR may be 50 to 5,000 nucleotides or longer. In some embodiments, the length of the 3'UTR may be 50 to 1,000 nucleotides or longer. In some embodiments, the length of the 3'UTR is about 50 nucleotides, about 100 nucleotides, about 150 nucleotides, about 200 nucleotides, about 250 nucleotides, about 300 nucleotides, about 350 nucleotides, about 400 nucleotides, about 450 nucleotides, about 500 nucleotides, about 550 nucleotides, about 600 nucleotides, about 650 nucleotides, about 700 nucleotides, about 7 ... In some embodiments, the mRNA disclosed herein may comprise a 5' or 3' UTR that is derived from a gene different from the gene encoded by the mRNA transcript (i.e., the UTR is a heterologous UTR).
[0092] In some embodiments, an mRNA disclosed herein may comprise a 5' or 3' UTR that is derived from a different gene than the gene encoded by the mRNA transcript (ie, the UTR is a heterologous UTR).
[0093] In certain embodiments, 5' and / or 3'UTR sequences are derived from stable mRNA (e.g., globin, actin, GAPDH, tubulin, histone or citric acid cycle enzymes) to increase the stability of mRNA. For example, the 5'UTR sequence may include a partial sequence of the CMV immediate early 1 (IE 1) gene or a fragment thereof to improve the nuclease resistance of mRNA and / or improve the half-life of mRNA. It is also contemplated that the sequence encoding human growth hormone (hGH) or a fragment thereof is included in the 3' end or untranslated region of mRNA. Typically, these modifications can improve the stability and / or pharmacokinetic properties (e.g., half-life) of mRNA relative to its unmodified counterpart, and include, for example, modifications made to improve the resistance of mRNA to nuclease digestion in vivo.
[0094] Exemplary 5'UTRs include a sequence derived from the CMV immediate early 1 (IE1) gene (U.S. Publication Nos. 2014 / 0206753 and 2015 / 0157565, each of which is incorporated herein by reference) or the sequence GGGAUCCUACC (SEQ ID NO: 20) (U.S. Publication No. 2016 / 0151409, which is incorporated herein by reference).
[0095] In various embodiments, 5'UTR is derived from the 5'UTR of TOP gene. TOP gene is typically characterized by the presence of 5'-terminal oligopyrimidine (TOP) bundle. In addition, most TOP genes are characterized by growth-related translation regulation. However, TOP genes with tissue-specific translation regulation are also known. In certain embodiments, the 5'UTR derived from the 5'UTR of TOP gene lacks 5'TOP motif (oligopyrimidine bundle) (e.g., U.S. Publication Nos. 2017 / 0029847, 2016 / 0304883, 2016 / 0235864 and 2016 / 0166710, each of which is incorporated herein by reference).
[0096] In certain embodiments, the 5'UTR is derived from the ribosomal protein large 32 (L32) gene (U.S. Publication No. 2017 / 0029847, supra).
[0097] In certain embodiments, the 5'UTR is derived from the 5'UTR of the hydroxysteroid (17-b) dehydrogenase 4 gene (HSD17B4) (U.S. Publication No. 2016 / 0166710, supra).
[0098] In certain embodiments, the 5'UTR is derived from the 5'UTR of the ATP5A1 gene (U.S. Publication No. 2016 / 0166710, supra).
[0099] In some embodiments, an internal ribosome entry site (IRES) is used in place of the 5'UTR.
[0100] In some embodiments, the 5'UTR comprises the nucleic acid sequence set forth in SEQ ID NO: 14. In some embodiments, the 3'UTR comprises the nucleic acid sequence set forth in SEQ ID NO: 15. The 5'UTR and 3'UTR are described in further detail in WO 2012075040, which is incorporated herein by reference. II.C. Polyadenylation tail
[0101] As used herein, the term "poly (A) sequence", or "poly (A) tail" or "poly (A) region" refers to the adenosine nucleotide sequence at the 3' end of an mRNA molecule. The poly (A) tail can impart stability to the mRNA and protect it from exonuclease degradation, and it is also believed that it can enhance translation. In some embodiments, the poly (A) tail is substantially homopolymeric, for example, a poly (A) tail such as 100 adenosine nucleotides is substantially 100 nucleotides in length. In other embodiments, the poly (A) tail may be interrupted by at least one nucleotide different from an adenosine nucleotide, for example, a poly (A) tail such as 100 adenosine nucleotides may be more than 100 nucleotides in length (comprising 100 adenosine nucleotides, in addition, the at least one nucleotide or a section of nucleotides is different from an adenosine nucleotide). In certain embodiments, the poly (A) tail comprises the sequence AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGCAUAUGACUAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA (SEQ ID NO: 21).
[0102] Typically, a "poly(A) tail" as defined herein relates to RNA, however, in the context of the present disclosure the term also relates to the corresponding sequence in a DNA molecule (eg, a "poly(T) sequence").
[0103] The poly(A) tail may comprise about 10 to about 500 adenosine nucleotides, about 10 to about 200 adenosine nucleotides, about 40 to about 200 adenosine nucleotides, or about 40 to about 150 adenosine nucleotides. The poly(A) tail may be at least about 10, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, or 500 adenosine nucleotides in length.
[0104] In some embodiments where the nucleic acid is RNA, the poly(A) tail of the nucleic acid is obtained from a DNA template during in vitro transcription of the RNA. In other embodiments, the poly(A) tail is obtained in vitro by conventional chemical synthesis methods without transcription from a DNA template. In other embodiments, the poly(A) tail is generated by enzymatic polyadenylation of the RNA (after in vitro transcription of the RNA) using commercially available polyadenylation kits and corresponding protocols known in the art, or alternatively, by using an immobilized poly(A) polymerase, for example using methods and means as described in WO 2016 / 174271.
[0105] The nucleic acid may comprise a poly(A) tail obtained by enzymatic polyadenylation, wherein most nucleic acid molecules comprise from about 100 (+ / - 20) to about 500 (+ / - 50) or about 250 (+ / - 20) adenosine nucleotides.
[0106] In other embodiments, the nucleic acid may comprise a poly(A) tail derived from the template DNA, and may additionally comprise at least one additional poly(A) tail generated by enzymatic polyadenylation, for example, as described in WO 2016 / 091391.
[0107] In further embodiments, the nucleic acid comprises at least one polyadenylation signal.
[0108] In other embodiments, the nucleic acid may comprise at least one poly(C) sequence.
[0109] As used herein, the term "poly (C) sequence" is intended to be a cytosine nucleotide sequence of up to about 200 cytosine nucleotides. In some embodiments, the poly (C) sequence comprises about 10 to about 200 cytosine nucleotides, about 10 to about 100 cytosine nucleotides, about 20 to about 70 cytosine nucleotides, about 20 to about 60 cytosine nucleotides, or about 10 to about 40 cytosine nucleotides. In certain exemplary embodiments, the poly (C) sequence comprises about 30 cytosine nucleotides. II.D. Chemical Modification
[0110] The mRNA disclosed herein can be modified or unmodified. In certain embodiments, the mRNA disclosed herein can contain one or more modifications that typically enhance RNA stability. Exemplary modifications include backbone modifications, sugar modifications, or base modifications. In some embodiments, the disclosed mRNA can be synthesized from naturally occurring nucleotides and / or nucleotide analogs (modified nucleotides), including but not limited to purines (adenine (A), guanine (G)) or pyrimidines (thymine (T), cytosine (C), uracil (U)) and analogs or derivatives of modified nucleotides purines and pyrimidines, such as, for example, 1-methyl-adenine, 2-methyl-adenine, 2-methylthio-N-6-isopentenyl-adenine, N6-methyl-adenine, N6-isopentenyl-adenine, 2-thio-cytosine, 3-methyl-cytosine, 4-acetyl-cytosine, 5-methyl-cytosine, 2,6-diaminopurine, 1-methyl-guanine, 2-methyl-guanine, 2,2-dimethyl-guanine, 7-methyl-guanine, inosine, 1-methyl-inosine, pseudouracil, uracil, dihydrouracil, 2-thiouracil, 4-thiouracil, 5-carboxymethylaminomethyl-2-thiouracil, 5-(carboxyhydroxymethyl)-uracil, 5-fluoro-uracil, 5-bromo-uracil, 5-carboxymethylaminomethyl-uracil, 5-methyl-2-thiouracil, 5-methyl-uracil, N-uracil-5-oxyacetate methyl ester, 5-methylamino Methyl-uracil, 5-methoxyaminomethyl-2-thio-uracil, 5'-methoxycarbonylmethyl-uracil, 5-methoxy-uracil, uracil-5-oxyacetate methyl ester, uracil-5-oxyacetate (v), 1-methyl-pseudouracil, quercetin, β-D-mannosyl-quercetin, phosphoramidite, phosphorothioate, peptide nucleotide, methylphosphonate, 7-deazaguanosine, 5-methylcytosine and inosine.
[0111] In some embodiments, the disclosed mRNA comprises at least one chemical modification, including but not limited to pseudouridine, N1-methylpseudouridine, 2-thiouridine, 4'-thiouridine, 5-methylcytosine, 2-thiol-1-methyl-1-deaza-pseudouridine, 2-thiol-1-methyl-pseudouridine, 2-thiol-5-aza-uridine, 2-thiol-dihydropseudouridine, 2-thiol-dihydrouridine, 2-thiol-pseudouridine, 4-methoxy-2-thiol-pseudouridine, 4-methoxy-pseudouridine, 4-thiol-1-methyl-pseudouridine, 4-thiol-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methyluridine, 5-methyluridine, 5-methoxyuridine and 2'-O-methyluridine.
[0112] In some embodiments, the chemical modification is selected from the group consisting of pseudouridine, N1-methylpseudouridine, 5-methylcytosine, 5-methoxyuridine, and combinations thereof.
[0113] In some embodiments, the chemical modification comprises N1-methylpseudouridine.
[0114] In some embodiments, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% of the uracil nucleotides in the mRNA are chemically modified.
[0115] In some embodiments, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, or 100% of the uracil nucleotides in an ORF are chemically modified.
[0116] The preparation of such analogs is known to those skilled in the art, for example, from U.S. Pat. No. 4,373,071, U.S. Pat. No. 4,401,796, U.S. Pat. No. 4,415,732, U.S. Pat. No. 4,458,066, U.S. Pat. No. 4,500,707, U.S. Pat. No. 4,668,777, U.S. Pat. No. 4,973,679, U.S. Pat. No. 5,047,524, U.S. Pat. No. 5,132,418, U.S. Pat. No. 5,153,319, U.S. Pat. No. 5,262,530, and U.S. Pat. No. 5,700,642. II.E.mRNA synthesis
[0117] The mRNA disclosed herein can be synthesized according to any of a variety of known methods. For example, the mRNA according to the present disclosure can be synthesized via in vitro transcription (IVT). Methods for in vitro transcription are known in the art. See, for example, Geall et al. (2013) Semin. Immunol. 25(2): 152-159; Brunelle et al., (2013) Methods Enzymol. 530: 101-14. Briefly, IVT is typically performed with a linear or circular DNA template containing a promoter, a ribonucleoside triphosphate pool, a buffer system that may include DTT and magnesium ions, and an appropriate RNA polymerase (e.g., T3, T7 or SP6 RNA polymerase), DNase I, pyrophosphatase and / or RNase inhibitor. The exact conditions will vary depending on the specific application. The presence of these reagents is undesirable in the final mRNA product and is considered an impurity or contaminant that must be purified to provide a clean and uniform mRNA suitable for therapeutic use. While in some embodiments it may be desirable to provide mRNA from an in vitro transcription reaction, other sources of mRNA may be used in accordance with the present disclosure, including wild-type mRNA produced by bacteria, fungi, plants, and / or animals.
[0118] In certain embodiments, the mRNA comprises at least the following structural elements: (i) a 5' cap having the following structure: (ii) a 5' untranslated region (5'UTR) having the nucleic acid sequence of SEQ ID NO: 14; (iii) at least one OspA open reading frame having the nucleic acid sequence of any one of SEQ ID NOs: 16-19; (iv) a 3' untranslated region (3'UTR) having the nucleic acid sequence of SEQ ID NO: 15; and (v) Poly A tail.
[0119] In certain embodiments, the poly(A) tail is from about 10 to about 500 adenosine nucleotides in length. III. OspA protein
[0120] The causative agent of Lyme disease is Borrelia bacterium. Four species of Borrelia cause most human diseases: Borrelia burgdorferi, Borrelia afforiensis, Borrelia garinii and Borrelia bavariae. Each Borrelia species has the surface expression of outer surface protein A (OspA), and OspA is a useful protein target for the vaccination for the treatment of Lyme disease. OspA exists with multiple serotypes, as defined by its reactivity with the monoclonal antibody for the different epitopes of OspA (see Wilske et al., J Clin Microbiol [Clinical Microbiology Magazine] 31 (2): 340-350 (1993)). These serotypes are related to the different gene species of Borrelia bacterium. In certain embodiments, OspA is any one of serotype 1-7 (ST1, ST2, ST3, ST4, ST5, ST6 or ST7). In certain embodiments, OspA is from Borrelia burgdorferi, Borrelia mayoni, Borrelia afforiensis, Borrelia garinii, Borrelia bavaria, Borrelia sparmannii, Borrelia lusitaniai, Borrelia biseti and / or Borrelia faresii. In certain embodiments, OspA is Borrelia burgdorferi OspA. In certain embodiments, Borrelia can be carried by the Ticks of Ixodes. In certain embodiments, Borrelia is Borrelia burgdorferi, Borrelia mayoni, Borrelia afforiensis, Borrelia garinii or Borrelia bavariai.
[0121] In one aspect, the present disclosure provides a Lyme disease vaccine comprising a messenger RNA (mRNA) comprising an open reading frame (ORF) encoding at least one antigenic polypeptide derived from at least one Borrelia bacterium.
[0122] In certain embodiments, the at least one antigenic polypeptide comprises at least one Borrelia lipoprotein.
[0123] In certain embodiments, at least one lipoprotein is OspA or its fragment or variant.Preferably, fragment or variant comprise at least 5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,30,35,40,45,50,60,70,80,90,100 amino acid.
[0124] In certain embodiments, the at least one OspA is derived from OspA serotype (ST) 1, 2, 3, 4, 5, 6 and / or 7.
[0125] In certain embodiments, the at least one OspA serotype 1-7 is from serotype 1 Borrelia burgdorferi strain B31, serotype 2 Borrelia afzawa strain PKO, serotype 3 Borrelia garinii strain PBr, serotype 4 Borrelia bavariae, serotype 5 Borrelia garinii, serotype 6 Borrelia garinii, or serotype 7 Borrelia garinii.
[0126] In certain embodiments, the OspA polypeptide is OspA serotype 1 (ST1). In certain embodiments, the OspA ST1 polypeptide comprises an amino acid sequence with at least 85% identity to SEQ ID NO:1. In certain embodiments, the OspA polypeptide is OspA serotype 1 (ST1). In certain embodiments, the OspA ST1 polypeptide comprises an amino acid sequence with 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to SEQ ID NO:1. SEQ ID NO:1 corresponds to the OspA from Borrelia burgdorferi strain B31 (serotype 1) NCBI sequence ID WP_010890378.1 (without its signal sequence and N-terminal methionine amino acid).
[0127] In certain embodiments, the OspA ST1 polypeptide is encoded by the nucleotide sequence shown in any one of SEQ ID NO: 10, 11, 16 or 17.
[0128] In certain embodiments, the OspA polypeptide is OspA serotype 2 (ST2). In certain embodiments, the OspA ST2 polypeptide comprises an amino acid sequence with at least 85% identity to SEQ ID NO:2. In certain embodiments, the OspA polypeptide is OspA serotype 2 (ST2). In certain embodiments, the OspA ST2 polypeptide comprises an amino acid sequence with 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to SEQ ID NO:2. SEQ ID NO:2 corresponds to the OspA from Borrelia afzini strain PKO (serotype 2) NCBI sequence WP_011703777.1 (without its signal sequence and N-terminal methionine amino acid).
[0129] In certain embodiments, the OspA ST2 polypeptide is encoded by the nucleotide sequence shown in any one of SEQ ID NO: 12, 13, 18 or 19.
[0130] In certain embodiments, the OspA polypeptide is OspA serotype 3 (ST3). In certain embodiments, the OspA ST3 polypeptide comprises an amino acid sequence with at least 85% identity to SEQ ID NO:3. In certain embodiments, the OspA polypeptide is OspA serotype 3 (ST3). In certain embodiments, the OspA ST3 polypeptide comprises an amino acid sequence with 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to SEQ ID NO:3. SEQ ID NO:3 corresponds to the OspA from Borrelia garinii strain PBr (serotype 3) GenBank: CAA56549.1 (without its signal sequence and N-terminal methionine amino acid).
[0131] In certain embodiments, the OspA polypeptide is OspA serotype 4 (ST4). In certain embodiments, the OspA ST4 polypeptide comprises an amino acid sequence with at least 85% homogeneity to SEQ ID NO:4. In certain embodiments, the OspA polypeptide is OspA serotype 4 (ST4). In certain embodiments, the OspA ST4 polypeptide comprises an amino acid sequence with 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% homogeneity to SEQ ID NO:4. SEQ ID NO:4 corresponds to the OspA from Borrelia bavariae (serotype 4) NCBI sequence WP_011187157.1 (without its signal sequence and N-terminal methionine amino acid).
[0132] In certain embodiments, the OspA polypeptide is OspA serotype 5 (ST5). In certain embodiments, the OspA ST5 polypeptide comprises an amino acid sequence with at least 85% identity to SEQ ID NO:5. In certain embodiments, the OspA polypeptide is OspA serotype 5 (ST5). In certain embodiments, the OspA ST5 polypeptide comprises an amino acid sequence with 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to SEQ ID NO:5. SEQ ID NO:5 corresponds to the OspA from Borrelia garinii (serotype 5) GenBank CAA59727.1 (without its signal sequence and N-terminal methionine amino acid).
[0133] In certain embodiments, the OspA polypeptide is OspA serotype 6 (ST6). In certain embodiments, the OspA ST6 polypeptide comprises an amino acid sequence with at least 85% identity to SEQ ID NO:6. In certain embodiments, the OspA polypeptide is OspA serotype 6 (ST6). In certain embodiments, the OspA ST6 polypeptide comprises an amino acid sequence with 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to SEQ ID NO:6. SEQ ID NO:6 corresponds to the OspA from Borrelia garinii (serotype 6) GenBank: CAA45010.1 (without its signal sequence and N-terminal methionine amino acid).
[0134] In certain embodiments, the OspA polypeptide is OspA serotype 7 (ST7). In certain embodiments, the OspA ST7 polypeptide comprises an amino acid sequence having at least 85% identity to SEQ ID NO:7. In certain embodiments, the OspA polypeptide is OspA serotype 7 (ST7). In certain embodiments, the OspA ST7 polypeptide comprises an amino acid sequence having 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to SEQ ID NO:7. SEQ ID NO:7 corresponds to OspA from Borrelia garinii (serotype 7) GenBank CAA56547.1 (without its signal sequence and N-terminal methionine amino acid). IV. Lipid Nanoparticles (LNP)
[0135] The LNPs of the present disclosure comprise four types of lipids: (i) ionizable lipids (eg, cationic lipids); (ii) PEGylated lipids; (iii) cholesterol-based lipids (eg, cholesterol); and (iv) helper lipids. A. Ionizable lipids
[0136] The ionizable lipid facilitates mRNA encapsulation and can be a cationic lipid. Cationic lipids provide a positively charged environment at low pH to facilitate efficient encapsulation of negatively charged mRNA drug substances.
[0137] In some embodiments, the cationic lipid is OF-02:
[0138] OF-02 is a non-degradable structural analogue of OF-Deg-Lin. OF-Deg-Lin contains a degradable ester bond to connect the diketopiperazine core and the diunsaturated tail, while OF-02 contains a non-degradable 1,2-amino-alcohol bond to connect the same diketopiperazine core and the diunsaturated tail (Fenton et al., Adv Mater. [Advanced Materials] (2016) 28: 2939; U.S. Patent No. 10,201,618). The exemplary LNP formulation (lipid A) herein contains OF-2.
[0139] In some embodiments, the cationic lipid is cKK-E10 (Dong et al., PNAS (2014) 111(11):3955-60; U.S. Pat. No. 9,512,073):
[0140] An exemplary LNP formulation herein (Lipid B) contains cKK-E10.
[0141] In some embodiments, the cationic lipid is GL-HEPES-E3-E10-DS-3-E18-1(2-(4-(2-((3-(bis((Z)-2-hydroxyoctadec-9-en-1-yl)amino)propyl)disulfanyl)ethyl)piperazin-1-yl)ethyl 4-(bis(2-hydroxydecyl)amino)butyrate), which is a HEPES-based disulfide cationic lipid with a piperazine core having Formula III:
[0142] An exemplary LNP formulation herein (lipid C) contains GL-HEPES-E3-E10-DS-3-E18-1. Lipid C has the same composition as lipid A or lipid B, except that the cationic lipid is different.
[0143] In some embodiments, the cationic lipid is GL-HEPES-E3-E12-DS-4-E10 (2-(4-(2-((3-(bis(2-hydroxydecyl)amino)butyl)disulfanyl)ethyl)piperazin-1-yl)ethyl 4-(bis(2-hydroxydodecyl)amino)butyrate), which is a HEPES-based disulfide cationic lipid with a piperazine core having Formula IV:
[0144] The exemplary LNP formulation herein (lipid D) contains GL-HEPES-E3-E12-DS-4-E10. Lipid D has the same composition as lipid A or lipid B, except that the cationic lipid is different.
[0145] In some embodiments, the cationic lipid is GL-HEPES-E3-E12-DS-3-E14 (2-(4-(2-((3-(bis(2-hydroxytetradecyl)amino)propyl)disulfanyl)ethyl)piperazin-1-yl)ethyl 4-(bis(2-hydroxydodecyl)amino)butyrate), which is a HEPES-based disulfide cationic lipid with a piperazine core having Formula V:
[0146] The exemplary LNP formulation (lipid E) herein contains GL-HEPES-E3-E12-DS-3-E14. Lipid E has the same composition as lipid A or lipid B, except that the cationic lipid is different.
[0147] Cationic lipids GL-HEPES-E3-E10-DS-3-E18-1 (III), GL-HEPES-E3-E12-DS-4-E10 (IV), and GL-HEPES-E3-E12-DS-3-E14 (V) can be synthesized according to the general procedure described in Scheme 1:
[0148] Scheme 1: General synthetic scheme for lipids of formula (III), (IV) and (V)
[0149] In some embodiments, the cationic lipid is MC3, which has Formula VI:
[0150] In some embodiments, the cationic lipid is SM-102 (9-heptadecyl 8-{(2-hydroxyethyl)[6-oxo-6-(undecyloxy)hexyl]amino}octanoate) having Formula VII:
[0151] In some embodiments, the cationic lipid is ALC-0315 [(4-hydroxybutyl)azanediyl]bis(hexane-6,1-diyl)bis(2-hexyldecanoate) having Formula VIII:
[0152] In some embodiments, the cationic lipid is cOrn-EE1, which has Formula IX:
[0153] In some embodiments, the cationic lipid can be selected from the group comprising the following: cKK-E10; OF-02; [(6Z,9Z,28Z,31Z)-triacontane-6,9,28,31-tetraen-19-yl] 4-(dimethylamino)butyrate (D-Lin-MC3-DMA); 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA); 1,2-dilinoleyloxy-N,N-dimethyl-3-aminopropane (DLin-DMA); di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (L319); 8- {(2-hydroxyethyl)[6-oxo-6-(undecyloxy)hexyl]amino}octanoic acid 9-heptadecyl ester (SM-102); [(4-hydroxybutyl)azanediyl]bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); [3-(dimethylamino)-2-[(Z)-octadec-9-enoyl]oxypropyl](Z)-octadec-9-enoate (DODAP); 2,5-bis(3-aminopropylamino)-N-[2-[di(heptadecyl)amino]-2-oxoethyl]pentanamide (DOGS); [(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[ (2R)-6-methylheptane-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3-yl] N-[2-(dimethylamino)ethyl]carbamate (DC-Chol); tetrakis(8-methylnonyl) 3,3′,3″,3″′-(((methylazanediyl)bis(propane-3,1-diyl))bis(azanetriyl))tetrapropionate (306Oi10); (2-(dioctylammonium)ethyl)decyl phosphate (9A1P9); 5,5-di((Z)-heptadeca-8-en-1-yl)-1-(3-(pyrrolidin-1-yl)propyl)-2,5-dihydro-1H- Ethyl imidazole-2-carboxylate (A2-Iso5-2DC18); bis(2-(dodecyldisulfanyl)ethyl)3,3'-((3-methyl-9-oxo-10-oxa-13,14-dithia-3,6-diazacosyl)azanediyl)dipropionate (BAME-O16B); 1,1'-((2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl)(2-hydroxydodecyl)amino)ethyl)piperazin-1-yl)ethyl)azanediyl)bis(dodecan-2-ol) (C12-200); 3,6-bis(4-(bis(2-hydroxydodecyl)amino)butyl)piperazine-2,5-dione (cKK-E12);Hexa(octan-3-yl) 9,9′,9″,9″′,9″″,9″′″-((((benzene-1,3,5-tricarbonyl)tri(azanediyl))tri(propane-3,1-diyl))tri(azanetriyl))hexanonanoate (FTT5); (((3,6-dioxopiperazine-2,5-diyl)bis(butane-4,1-diyl))bis(azanetriyl))tetra(ethane-2,1-diyl)(9Z,9′Z,9″Z,9″′Z,12Z,12′Z,12″Z,12″′Z)-tetra(octadec-9,12-dienoate) (OF-Deg-Lin); TT3; N; 1 ,N 3 ,N 5 -Tris(3-(didodecylamino)propyl)benzene-1,3,5-tricarboxamide; N1-[2-((1S)-1-[(3-aminopropyl)amino]-4-[bis(3-aminopropyl)amino]butylcarboxamido)ethyl]-3,4-di[oleyloxy]-benzamide (MVL5); 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoic acid heptadecan-9-yl ester (lipid 5); GL-HEPES-E3-E10-DS-3-E18-1; GL-HEPES-E3-E12-DS-4-E10; GL-HEPES-E3-E12-DS-3-E14; and combinations thereof.
[0154] In some embodiments, the cationic lipid is biodegradable.
[0155] In some embodiments, the cationic lipid is not biodegradable.
[0156] In some embodiments, the cationic lipid is cleavable.
[0157] In some embodiments, the cationic lipid is not cleavable.
[0158] Cationic lipids are further described in detail in Dong et al. (PNAS. [Proceedings of the National Academy of Sciences of the United States of America] 111(11):3955-60.2014); Fenton et al. (Adv Mater. [Advanced Materials] 28:2939.2016); U.S. Patent No. 9,512,073; and U.S. Patent No. 10,201,618, each of which is incorporated herein by reference. B. PEGylated lipids
[0159] The lipid component of PEGylation provides control of the granularity and stability of nanoparticles. The addition of such components can prevent complex aggregation, and provides means for increasing the circulation life of lipid-nucleic acid pharmaceutical compositions and increasing their delivery to target tissues (FEBS Letters [European Biochemical Society Federation Express] 268 (1) by Klibanov et al.: 235-7.1990). These components can be selected to quickly exchange pharmaceutical compositions in vivo (see, e.g., U.S. Patent number 5,885,613).
[0160] Contemplated PEGylated lipids include, but are not limited to, polyethylene glycol (PEG) chains up to 5 kDa in length covalently attached to C6-C 20 (e.g., C8, C 10 , C 12 , C 14 , C 16 or C 18 ) in length, such as a derivatized ceramide (e.g., N-octanoyl-sphingosine-1-[succinyl(methoxypolyethylene glycol)] (C8 PEG ceramide)). In some embodiments, the PEGylated lipid is 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol (DMG-PEG); 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-polyethylene glycol (DSPE-PEG); 1,2-dilauroyl-sn-glycero-3-phosphoethanolamine-polyethylene glycol (DLPE-PEG); 1,2-distearoyl-rac-glycero-polyethylene glycol (DSG-PEG); PEG-DAG; PEG-PE; PEG-S-DAG; PEG-S-DMG; PEG-cer; PEG-dialkoxypropylcarbamate; 2-[(polyethylene glycol)-2000]-N,N-ditetradecanoylacetamide (ALC-0159); and combinations thereof.
[0161] In certain embodiments, PEG has a high molecular weight, such as 2000-2400 g / mol. In certain embodiments, PEG is PEG2000 (or PEG-2K). In certain embodiments, the PEGylated lipid herein is DMG-PEG2000, DSPE-PEG2000, DLPE-PEG2000, DSG-PEG2000, C8 PEG2000, or ALC-0159 (2-[(polyethylene glycol)-2000]-N, N-di-tetradecyl acetamide). In certain embodiments, the PEGylated lipid herein is DMG-PEG2000. C. Cholesterol-based lipids
[0162] The cholesterol component provides stability for the lipid bilayer structure in the nanoparticle. In some embodiments, LNP comprises one or more cholesterol-based lipids. Suitable cholesterol-based lipids include, for example: DC-Choi (N, N-dimethyl-N-ethylformylamino cholesterol), l,4-bis (3-N-oleylamino-propyl) piperazine (Gao et al., Biochem Biophys Res Comm. (1991) 179:280; Wolf et al., BioTechniques (1997) 23:139; U.S. Pat. No. 5,744,335), imidazole cholesterol ester ("ICE"; WO2011 / 068810), sitosterol (22,23-dihydrostigmasterol), β-sitosterol, sitostanol, fuccasterol, stigmasterol (stigmasterane-5,22-dien-3-ol), ergosterol; streptosterol (3β-hydroxy-5,24-cholestadiene); lanosterol (8,24-lanostadien-3b-ol); 7-dehydrocholesterol (Δ5,7-cholestadiene); sterol); dihydrolanosterol (24,25-dihydrolanosterol); yeast sterol (5α-cholesta-8,24-dien-3β-ol); lathosterol (5α-cholesta-7-en-3β-ol); diosgenin ((3β,25R)-spirostan-5-en-3-ol); campesterol (campester-5-en-3β-ol); campestanol (5a-campestan-3b-ol); 24-methylene cholesterol (5,24(28)-cholesta-dien-24-methylen-3β-ol); cholesterol margarate (cholester-5-en-3β-yl heptadecanoate); cholesterol oleate; cholesterol stearate and other modified forms of cholesterol. In some embodiments, the cholesterol-based lipid used in the LNP is cholesterol. D. Helper lipids
[0163] The helper lipid enhances the structural stability of the LNP and explains the escape of the LNP in the endosome. It improves the uptake and release of the mRNA drug payload. In some embodiments, the helper lipid is a zwitterionic lipid that has a fusogenic property for enhancing the uptake and release of the drug payload. Examples of helper lipids are 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE); 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC); 1,2-dioleoyl-sn-glycero-3-phospho-L-serine (DOPS); 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DEPE); and 1,2-dioleoyl-sn-glycero-3-phosphocholine (DPOC), dipalmitoylphosphatidylcholine (DPPC), DMPC, 1,2-dilauroyl-sn-glycero-3-phosphocholine (DLPC), 1,2-distearoylphosphatidylethanolamine (DSPE), and 1,2-dilauroyl-sn-glycero-3-phosphoethanolamine (DLPE).
[0164] Other exemplary helper lipids are dioleoylphosphatidylcholine (DOPC), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoyl-phosphatidylethanolamine (POPE), dioleoyl-phosphatidylethanolamine 4-(N-maleimidomethyl)-cyclohexane-l-carboxylate (DOPE-mal), dipalmitoylphosphatidylethanolamine (DPPE), dimyristoylphosphatidylethanolamine (DMPE), phosphatidylserine, sphingolipids, sphingomyelin, ceramides, cerebrosides, gangliosides, 16-O-monomethyl PE, 16-O-dimethyl PE, 18-1-trans PE, l-stearoyl-2-oleoyl-phosphatidylethanolamine (SOPE) or a combination thereof. In certain embodiments, the helper lipid is DOPE. In certain embodiments, the helper lipid is DSPC.
[0165] In other embodiments, the present LNPs comprise (i) SM-102; (ii) DMG-PEG2000; (iii) cholesterol; and (iv) DSPC.
[0166] In other embodiments, the present LNPs comprise (i) ALC-0315; (ii) ALC-0159; (iii) cholesterol; and (iv) DSPC.
[0167] In other embodiments, the present LNPs comprise (i) OF-02; (ii) DMG-PEG2000; cholesterol; and (iv) DOPE.
[0168] In other embodiments, the present LNP comprises (i) cKK-E10; (ii) DMG-PEG2000; (iii) cholesterol; and (iv) DOPE.
[0169] In other embodiments, the present LNP comprises (i) GL-HEPES-E3-E10-DS-3-E18-1; (ii) DMG-PEG2000; (iii) cholesterol; and (iv) DOPE.
[0170] In other embodiments, the present LNP comprises (i) GL-HEPES-E3-E12-DS-4-E10; (ii) DMG-PEG2000; (iii) cholesterol; and (iv) DOPE.
[0171] In other embodiments, the present LNP comprises (i) GL-HEPES-E3-E12-DS-3-E14; (ii) DMG-PEG2000; (iii) cholesterol; and (iv) DOPE. E. Molar ratio of lipid components
[0172] The mol ratio of the above-mentioned components is important for the effectiveness of LNP in delivering mRNA. The mol ratio of cationic lipids, PEGylated lipids, lipids based on cholesterol and auxiliary lipids is A: B: C: D, wherein A + B + C + D = 100%. In certain embodiments, the mol ratio of cationic lipids relative to total lipids (i.e., A) in LNP is 35%-55%, such as 35%-50% (e.g., 38%-42%, such as 40% or 45%-50%). In certain embodiments, the mol ratio of the lipid components of PEGylated relative to total lipids (i.e., B) is 0.25%-2.75% (e.g., 1%-2%, such as 1.5%). In certain embodiments, the mol ratio of lipids based on cholesterol relative to total lipids (i.e., C) is 20%-50% (e.g., 27%-30%, such as 28.5% or 38%-43%). In some embodiments, the molar ratio of the helper lipid to the total lipid (i.e., D) is 5%-35% (e.g., 28%-32%, such as 30% or 8%-12%, such as 10%). In some embodiments, the (PEGylated lipid + cholesterol) component has the same molar amount as the helper lipid. In some embodiments, the molar ratio of the cationic lipid to the helper lipid contained in the LNP is greater than 1.
[0173] In certain embodiments, the LNPs of the present disclosure comprise:
[0174] 35% to 55% or 40% to 50% cationic lipid in a molar ratio (e.g., 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54% or 55% cationic lipid in a molar ratio);
[0175] A polyethylene glycol (PEG) conjugated (PEGylated) lipid at a molar ratio of between 0.25% and 2.75% or between 1.00% and 2.00% (e.g., a molar ratio of 0.25%, 0.50%, 0.75%, 1.00%, 1.25%, 1.50%, 1.75%, 2.00%, 2.25%, 2.50%, or 2.75% PEGylated lipid);
[0176] 20% to 50%, 25% to 45%, or 28.5% to 43% cholesterol-based lipids (e.g., 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, or 50% cholesterol-based lipids); and
[0177] 5% to 35%, 8% to 30%, or 10% to 30% of a helper lipid in a molar ratio (e.g., a 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, or 35% helper lipid in a molar ratio),
[0178] All molar ratios are relative to the total lipid content of the LNP.
[0179] In certain embodiments, the LNP comprises: a cationic lipid at a molar ratio of 40%; a PEGylated lipid at a molar ratio of 1.5%; a cholesterol-based lipid at a molar ratio of 28.5%; and a helper lipid at a molar ratio of 30%.
[0180] In certain embodiments, the LNPs of the present disclosure comprise: a cationic lipid at a molar ratio of 45% to 50%; a PEGylated lipid at a molar ratio of 1.5% to 1.7%; a cholesterol-based lipid at a molar ratio of 38% to 43%; and a helper lipid at a molar ratio of 9% to 10%.
[0181] In certain embodiments, the PEGylated lipid is dimyristoyl-PEG2000 (DMG-PEG2000).
[0182] In certain embodiments, the cholesterol-based lipid is cholesterol.
[0183] In certain embodiments, the helper lipid is 1,2-dioleoyl-SN-glycero-3-phosphoethanolamine (DOPE).
[0184] In certain embodiments, the LNP comprises: OF-02 at a molar ratio of 35% to 55%; DMG-PEG2000 at a molar ratio of 0.25% to 2.75%; cholesterol at a molar ratio of 20% to 50%; and DOPE at a molar ratio of 5% to 35%.
[0185] In certain embodiments, the LNP comprises: cKK-E10 at a molar ratio of 35% to 55%; DMG-PEG2000 at a molar ratio of 0.25% to 2.75%; cholesterol at a molar ratio of 20% to 50%; and DOPE at a molar ratio of 5% to 35%.
[0186] In certain embodiments, the LNP comprises: GL-HEPES-E3-E10-DS-3-E18-1 at a molar ratio of 35% to 55%; DMG-PEG2000 at a molar ratio of 0.25% to 2.75%; cholesterol at a molar ratio of 20% to 50%; and DOPE at a molar ratio of 5% to 35%.
[0187] In certain embodiments, the LNP comprises: GL-HEPES-E3-E12-DS-4-E10 at a molar ratio of 35% to 55%; DMG-PEG2000 at a molar ratio of 0.25% to 2.75%; cholesterol at a molar ratio of 20% to 50%; and DOPE at a molar ratio of 5% to 35%.
[0188] In certain embodiments, the LNP comprises: GL-HEPES-E3-E12-DS-3-E14 at a molar ratio of 35% to 55%; DMG-PEG2000 at a molar ratio of 0.25% to 2.75%; cholesterol at a molar ratio of 20% to 50%; and DOPE at a molar ratio of 5% to 35%.
[0189] In certain embodiments, the LNP comprises: SM-102 at a molar ratio of 35% to 55%; DMG-PEG2000 at a molar ratio of 0.25% to 2.75%; cholesterol at a molar ratio of 20% to 50%; and DSPC at a molar ratio of 5% to 35%.
[0190] In certain embodiments, the LNP comprises: ALC-0315 at a molar ratio of 35% to 55%; ALC-0159 at a molar ratio of 0.25% to 2.75%; cholesterol at a molar ratio of 20% to 50%; and DSPC at a molar ratio of 5% to 35%.
[0191] In certain embodiments, the LNP comprises: OF-02 at a molar ratio of 40%; DMG-PEG2000 at a molar ratio of 1.5%; cholesterol at a molar ratio of 28.5%; and DOPE at a molar ratio of 30%. This LNP formulation is designated herein as "Lipid A".
[0192] In certain embodiments, the LNP comprises: 40% cKK-E10 at a molar ratio; 1.5% DMG-PEG2000 at a molar ratio; 28.5% cholesterol at a molar ratio; and 30% DOPE at a molar ratio. This LNP formulation is designated herein as "Lipid B".
[0193] In certain embodiments, the LNP comprises: 40% GL-HEPES-E3-E10-DS-3-E18-1 at a molar ratio; 1.5% DMG-PEG2000 at a molar ratio; 28.5% cholesterol at a molar ratio; and 30% DOPE at a molar ratio. This LNP formulation is designated herein as "Lipid C".
[0194] In certain embodiments, the LNP comprises: 40% GL-HEPES-E3-E12-DS-4-E10 at a molar ratio; 1.5% DMG-PEG2000 at a molar ratio; 28.5% cholesterol at a molar ratio; and 30% DOPE at a molar ratio. This LNP formulation is designated herein as "Lipid D".
[0195] In certain embodiments, the LNP comprises: 40% GL-HEPES-E3-E12-DS-3-E14 at a molar ratio; 1.5% DMG-PEG2000 at a molar ratio; 28.5% cholesterol at a molar ratio; and 30% DOPE at a molar ratio. This LNP formulation is designated herein as "Lipid E".
[0196] In certain embodiments, the LNP comprises: 50% molar ratio of 8-{(2-hydroxyethyl)[6-oxo-6-(undecanyloxy)hexyl]amino}octanoic acid 9-heptadecyl ester (SM-102); 10% molar ratio of 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC); 38.5% molar ratio of cholesterol; and 1.5% molar ratio of 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (DMG-PEG2000).
[0197] In certain embodiments, the LNP comprises: (4-hydroxybutyl)azanediyl]bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315) at a molar ratio of 46.3%; 1,2-distearoyl-sn-glycero-3-phosphorylcholine (DSPC) at a molar ratio of 9.4%; cholesterol at a molar ratio of 42.7%; and 2-[(polyethylene glycol)-2000]-N,N-ditetradecanoylacetamide (ALC-0159) at a molar ratio of 1.6%.
[0198] In certain embodiments, the LNP comprises: (4-hydroxybutyl)azanediyl]bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315) at a molar ratio of 47.4%; 1,2-distearoyl-sn-glycero-3-phosphorylcholine (DSPC) at a molar ratio of 10%; cholesterol at a molar ratio of 40.9%; and 2-[(polyethylene glycol)-2000]-N,N-ditetradecanoylacetamide (ALC-0159) at a molar ratio of 1.7%.
[0199] To calculate the actual amount of each lipid to be placed in the LNP formulation, first determine the molar amount of the cationic lipid based on the desired N / P ratio, where N is the number of nitrogen atoms in the cationic lipid, and P is the number of phosphate groups in the mRNA to be transported by the LNP. Next, calculate the molar amount of each other lipid based on the molar amount of the cationic lipid and the selected molar ratio. These molar amounts are then converted to weight using the molecular weight of each lipid. F. Active ingredients of LNP
[0200] The active ingredient of the LNP vaccine composition of the present invention is a nucleic acid (eg, mRNA) encoding an antigenic polypeptide derived from at least one Borrelia bacterium.
[0201] If necessary, LNP can be multivalent.In certain embodiments, LNP can carry nucleic acid, such as mRNA, and its coding is derived from more than one antigen polypeptide of at least one Borrelia bacterium, such as two, three, four, five, six, seven or eight antigens.For example, this LNP can carry multiple nucleic acids (for example, mRNA), and every kind of nucleic acid encoding is derived from the different antigen polypeptides of at least one Borrelia bacterium; Or carry and can be translated into the polycistronic mRNA (for example, each antigen encoding sequence is separated by the nucleotide joint of the self-cleavage peptide such as 2A peptide) of more than one antigen polypeptide that is derived from at least one Borrelia bacterium.The LNP carrying different nucleic acids (for example, mRNA) typically comprises (encapsulates) multiple copies of every kind of nucleic acid.For example, the LNP carrying or encapsulating two kinds of different nucleic acids typically carries multiple copies of every kind of nucleic acid in these two kinds of different nucleic acids.
[0202] In some embodiments, a single LNP formulation can comprise multiple (e.g., two, three, four, five, six, seven, eight, nine, ten, or more) LNPs, each carrying a different nucleic acid (e.g., mRNA).
[0203] When the nucleic acid is an mRNA, the mRNA can be unmodified (i.e., containing only natural ribonucleotides A, U, C, and / or G linked by phosphodiester bonds), or can be chemically modified (e.g., including nucleotide analogs such as pseudouridine (e.g., N-1-methylpseudouridine), 2'-fluororibonucleotides, and 2'-methoxyribonucleotides; and / or phosphorothioate bonds). The mRNA molecule can include a 5' cap and a poly A tail. G. Buffer and other components
[0204] In order to stabilize nucleic acids and / or LNPs (e.g., to extend the shelf life of vaccine products), to facilitate the administration of LNP pharmaceutical compositions, and / or to enhance the in vivo expression of nucleic acids, nucleic acids and / or LNPs can be formulated in combination with one or more carriers, targeting ligands, stabilizing agents (e.g., preservatives and antioxidants), and / or other pharmaceutically acceptable excipients. Examples of such excipients are parabens, thimerosal, thimerosal sodium, chlorobutanol, benzalkonium chloride, and chelating agents (e.g., EDTA).
[0205] The LNP compositions of the present disclosure can be provided as frozen liquid form or lyophilized form. Various cryoprotectants can be used, including but not limited to sucrose, trehalose, glucose, mannitol, mannose, dextrose, etc. Cryoprotectants can constitute 5%-30% (w / v) of the LNP compositions. In certain embodiments, the LNP compositions include trehalose, for example, 5%-30% (e.g., 10%) (w / v). Once prepared with cryoprotectants, the LNP compositions can be frozen (or lyophilized and frozen) at -20°C to -80°C.
[0206] The LNP composition can be provided to the patient in an aqueous buffer solution: thawed if previously frozen, or reconstituted in an aqueous buffer solution at the bedside if previously lyophilized. Typically, the buffer solution is isotonic and suitable for, e.g., intramuscular or intradermal injection. In some embodiments, the buffer solution is phosphate buffered saline (PBS). V. Methods for Making LNP Vaccines
[0207] The LNP of the present invention can be prepared by various techniques currently known in the art. For example, multilamellar vesicles (MLVs) can be prepared according to conventional techniques, such as by depositing the selected lipids on the inner wall of a suitable container or vessel (by dissolving the lipids in an appropriate solvent and then evaporating the solvent to leave a thin film inside the vessel) or by spray drying. The aqueous phase can then be added to the vessel with a vortex motion, which allows the MLV to form. Unilamellar vesicles (ULVs) can then be formed by homogenizing, ultrasonicating or extruding the multilamellar vesicles. In addition, unilamellar vesicles can be formed by detergent removal techniques.
[0208] Various methods are described in US2011 / 0244026, US2016 / 0038432, US 2018 / 0153822, US2018 / 0125989 and US2021 / 0046192, and can be used to practice this disclosure. An exemplary method needs to be encapsulated mRNA by mixing it with a mixture of lipids, without first preforming lipid nanoparticles, as described in US2016 / 0038432. Another exemplary method needs to be encapsulated mRNA by mixing preformed LNP with mRNA, as described in US 2018 / 0153822.
[0209] In some embodiments, the method for preparing the LNP of loaded mRNA includes the step of heating one or more solutions to a temperature greater than ambient temperature, and the one or more solutions are solutions comprising preformed lipid nanoparticles, solutions comprising mRNA, and mixed solutions comprising mRNA encapsulated by LNP. In some embodiments, the method includes the step of heating one or both of mRNA solution and preformed LNP solution before the mixing step. In some embodiments, the method includes heating one or more of the solutions comprising preformed LNP, mRNA, and mRNA encapsulated by LNP during the mixing step. In some embodiments, the method includes the step of heating the mRNA encapsulated by LNP after the mixing step. In some embodiments, one or more solutions are heated to or greater than the following temperature: about 30°C, 37°C, 40°C, 45°C, 50°C, 55°C, 60°C, 65°C, or 70°C. In some embodiments, one or more solutions are heated to a temperature in the range of about 25° C.-70° C., about 30° C.-70° C., about 35° C.-70° C., about 40° C.-70° C., about 45° C.-70° C., about 50° C.-70° C., or about 60° C.-70° C. In some embodiments, the temperature is about 65° C.
[0210] Various methods can be used to prepare mRNA solutions suitable for the present disclosure. In certain embodiments, mRNA can be directly dissolved in a buffer solution as described herein. In certain embodiments, mRNA stock solutions can be produced by mixing mRNA stock solutions with buffer solutions before mixing with a lipid solution for encapsulation. In certain embodiments, mRNA stock solutions can be produced by mixing mRNA stock solutions with buffer solutions immediately before mixing with a lipid solution for encapsulation. In certain embodiments, suitable mRNA stock solutions can contain mRNA at a concentration of or greater than about 0.2 mg / ml, 0.4 mg / ml, 0.5 mg / ml, 0.6 mg / ml, 0.8 mg / ml, 1.0 mg / ml, 1.2 mg / ml, 1.4 mg / ml, 1.5 mg / ml, or 1.6 mg / ml, 2.0 mg / ml, 2.5 mg / ml, 3.0 mg / ml, 3.5 mg / ml, 4.0 mg / ml, 4.5 mg / ml or 5.0 mg / ml in water or buffer.
[0211] In certain embodiments, a pump is used to mix the mRNA stock solution with a buffer solution. Exemplary pumps include, but are not limited to, gear pumps, peristaltic pumps, and centrifugal pumps. Typically, the buffer solution is mixed at a rate greater than the rate of the mRNA stock solution. For example, the buffer solution can be mixed at a rate of at least 1x, 2x, 3x, 4x, 5x, 6x, 7x, 8x, 9x, 10x, 15x, or 20x of the rate of the mRNA stock solution. In certain embodiments, the buffer solution is mixed at a flow rate of about 100-6000ml / minute (e.g., about 100-300ml / minute, 300-600ml / minute, 600-1200ml / minute, 1200-2400ml / minute, 2400-3600ml / minute, 3600-4800ml / minute, 4800-6000ml / minute, or 60-420ml / minute). In some embodiments, the buffer solution is mixed at a flow rate of about 60 ml / min, 100 ml / min, 140 ml / min, 180 ml / min, 220 ml / min, 260 ml / min, 300 ml / min, 340 ml / min, 380 ml / min, 420 ml / min, 480 ml / min, 540 ml / min, 600 ml / min, 1200 ml / min, 2400 ml / min, 3600 ml / min, 4800 ml / min, or 6000 ml / min.
[0212] In some embodiments, the mRNA stock solution is mixed at a flow rate ranging from about 10-600 ml / min (e.g., about 5-50 ml / min, about 10-30 ml / min, about 30-60 ml / min, about 60-120 ml / min, about 120-240 ml / min, about 240-360 ml / min, about 360-480 ml / min, or about 480-600 ml / min). In some embodiments, the mRNA stock solution is mixed at a flow rate of about 5 ml / min, 10 ml / min, 15 ml / min, 20 ml / min, 25 ml / min, 30 ml / min, 35 ml / min, 40 ml / min, 45 ml / min, 50 ml / min, 60 ml / min, 80 ml / min, 100 ml / min, 200 ml / min, 300 ml / min, 400 ml / min, 500 ml / min, or 600 ml / min.
[0213] The process of incorporating the desired mRNA into lipid nanoparticles is referred to as "loading". Exemplary methods are described in Lasic et al., FEBS Lett. [FEBS Newsletter] (1992) 312: 255-8. The nucleic acid incorporated into the LNP can be completely or partially located in the internal space of the lipid nanoparticle, within the bilayer membrane of the lipid nanoparticle membrane, or associated with the outer surface of the lipid nanoparticle membrane. Incorporating mRNA into lipid nanoparticles is also referred to as "encapsulation" herein, wherein the nucleic acid is completely or substantially contained in the internal space of the lipid nanoparticle.
[0214] Suitable LNP can be prepared in various sizes. In certain embodiments, the lipid nanoparticle size that reduces is relevant to the more effective delivery of mRNA. The site of target cell or tissue and the application that lipid nanoparticle will be used for to some extent can be considered in selecting appropriate LNP size.
[0215] Various methods known in the art can be used to adjust the size of lipid nanoparticle populations. Exemplary methods herein utilize Zetasizer Nano ZS (Malvern Panalytical) to measure LNP particle size. In one approach, 10 μl of LNP sample is mixed with 990 μl of 10% trehalose. This solution is loaded into a cuvette and then placed in a Zetasizer machine. The z-average diameter (nm) or cumulative mean value is considered to be the average size of the LNP in the sample. The Zetasizer machine can also be used to measure the polydispersity index (PDI) by using dynamic light scattering (DLS) and cumulative analysis of autocorrelation functions. The average LNP diameter can be reduced by ultrasonic treatment of the formed LNP. Intermittent ultrasonic treatment cycles can be alternated with quasi-elastic light scattering (QELS) assessments to guide effective lipid nanoparticle synthesis.
[0216] In some embodiments, a majority of the purified LNPs (i.e., greater than about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% of the LNPs) have a size of about 70-150 nm (e.g., about 145 nm, about 140 nm, about 135 nm, about 130 nm, about 125 nm, about 120 nm, about 115 nm, about 110 nm, about 105 nm, about 100 nm, about 95 nm, about 90 nm, about 85 nm, or about 80 nm). In some embodiments, substantially all (e.g., greater than 80% or 90%) of the purified lipid nanoparticles have a size of about 70-150 nm (e.g., about 145 nm, about 140 nm, about 135 nm, about 130 nm, about 125 nm, about 120 nm, about 115 nm, about 110 nm, about 105 nm, about 100 nm, about 95 nm, about 90 nm, about 85 nm, or about 80 nm).
[0217] In certain embodiments, the LNPs have an average diameter of 30-200 nm.
[0218] In certain embodiments, the LNPs have an average diameter of 80-150 nm.
[0219] In some embodiments, the average size of the LNPs in the compositions of the present invention is less than 150 nm, less than 120 nm, less than 100 nm, less than 90 nm, less than 80 nm, less than 70 nm, less than 60 nm, less than 50 nm, less than 30 nm, or less than 20 nm.
[0220] In some embodiments, greater than about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% of the LNPs in the compositions of the invention range in size from about 40-90 nm (e.g., about 45-85 nm, about 50-80 nm, about 55-75 nm, about 60-70 nm), about 40-90 nm (e.g., about 45-85 nm, about 50-80 nm, about 55-75 nm, about 60-70 nm), or about 50-70 nm (e.g., 55-65 nm), which is particularly suitable for pulmonary delivery via aerosolization.
[0221] In some embodiments, the dispersibility or molecular size heterogeneity measure (PDI) of the LNPs in the pharmaceutical compositions provided by the present disclosure is less than about 0.5. In some embodiments, the PDI of the LNPs is less than about 0.5, less than about 0.4, less than about 0.3, less than about 0.28, less than about 0.25, less than about 0.23, less than about 0.20, less than about 0.18, less than about 0.16, less than about 0.14, less than about 0.12, less than about 0.10, or less than about 0.08. The PDI can be measured by a Zetasizer machine as described above.
[0222] In some embodiments, the pharmaceutical compositions provided herein are greater than about 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% of the purified LNPs encapsulate mRNA in each separate particle. In some embodiments, substantially all (e.g., greater than 80% or 90%) of the purified lipid nanoparticles in the pharmaceutical compositions are encapsulated in mRNA in each separate particle. In some embodiments, the encapsulation efficiency of lipid nanoparticles is 50% to 99%; or greater than about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 92%, 95%, 98% or 99%. Typically, the encapsulation efficiency of the lipid nanoparticles used in this article is at least 90% (e.g., at least 91%, 92%, 93%, 94% or 95%).
[0223] In some embodiments, the N / P ratio of the LNP is between 1 and 10. In some embodiments, the N / P ratio of the lipid nanoparticle is greater than 1, about 1, about 2, about 3, about 4, about 5, about 6, about 7, or about 8. In further embodiments, the N / P ratio of a typical LNP herein is 4.
[0224] In some embodiments, the pharmaceutical composition according to the present disclosure contains at least about 0.5 μg, 1 μg, 5 μg, 10 μg, 100 μg, 500 μg or 1000 μg of encapsulated mRNA. In some embodiments, the pharmaceutical composition contains about 0.1 μg to 1000 μg, at least about 0.5 μg, at least about 0.8 μg, at least about 1 μg, at least about 5 μg, at least about 8 μg, at least about 10 μg, at least about 50 μg, at least about 100 μg, at least about 500 μg or at least about 1000 μg of encapsulated mRNA.
[0225] In some embodiments, mRNA can be prepared by chemical synthesis or by in vitro transcription (IVT) of a DNA template. An exemplary method for preparing and purifying mRNA is described in Example 1. In this method, during the IVT process, a cDNA template is used to generate mRNA transcripts, and the DNA template is degraded by DNase. The transcripts are purified by depth filtration and tangential flow filtration (TFF). The purified transcripts are further modified by adding caps and tails, and the modified RNA is purified again by depth filtration and TFF.
[0226] The mRNA is then prepared in an aqueous buffer, and mixed with the amphipathic solution of the lipid component containing LNP. The amphipathic solution for dissolving four kinds of lipid components of LNP can be an alcoholic solution. In certain embodiments, alcohol is ethanol. The aqueous buffer can be, for example, citrate, phosphate, acetate or succinate buffer, and can have a pH of about 3.0-7.0 (for example, about 3.5, about 4.0, about 4.5, about 5.0, about 5.5, about 6.0 or about 6.5). The buffer can contain other components, such as salt (for example, sodium, potassium and / or calcium salt). In a particular embodiment, the aqueous buffer has 1mM citrate, 150mMNaCl, pH 4.5.
[0227] An exemplary non-limiting method for preparing mRNA-LNP compositions involves mixing a buffered mRNA solution with an ethanol solution of lipid in a controlled uniform manner, wherein lipid:mRNA ratio is maintained throughout the mixing process. In this illustrative example, mRNA is presented in an aqueous buffer containing citric acid monohydrate, trisodium citrate dihydrate and sodium chloride. The mRNA solution is added to a solution (1mM citrate buffer, 150mM NaCl, pH 4.5). A lipid mixture of four lipids (e.g., cationic lipids, PEGylated lipids, cholesterol-based lipids and auxiliary lipids) is dissolved in ethanol. Aqueous mRNA solution and ethanol lipid solution are mixed in a "T" shaped mixer with a nearly "pulseless" pump system at a volume ratio of 4:1. Then downstream purification and buffer exchange are carried out to the resulting mixture. Buffer exchange can be achieved using a dialysis cassette or a TFF system. TFF can be used to concentrate and buffer exchange the resulting nascent LNP immediately after formation via the T mixing process. The diafiltration process is a continuous operation, and the volume is kept constant by adding an appropriate buffer at the same rate as the permeate flow. VI. Packaging and Use of mRNA-LNP OspA Vaccine
[0228] The mRNA-LNP vaccine can be formulated or packaged for parenteral (e.g., intramuscular, intradermal or subcutaneous) administration or nasopharyngeal (e.g., intranasal) administration. The vaccine composition can be in the form of a ready-to-use formulation, wherein the LNP composition is lyophilized and reconstituted with a physiological buffer (e.g., PBS) just before use. The vaccine composition can also be shipped and provided in the form of an aqueous solution or frozen aqueous solution, and can be directly administered to a subject without reconstitution (if previously frozen, then after thawing).
[0229] Thus, the present disclosure provides an article (e.g., a kit) that provides an mRNA-LNP vaccine in a single container, or provides an mRNA-LNP vaccine in one container and a physiological buffer for reconstitution in another container. The one or more containers may contain a single-use dose or multiple-use doses. The container may be a pre-treated glass vial or ampoule. The article may also include instructions for use.
[0230] In certain embodiments, mRNA-LNP vaccines are provided for use in intramuscular (IM) injection. The vaccine can be injected into the subject's deltoid muscle, for example, in his / her upper arm. In certain embodiments, the vaccine is provided in a pre-filled syringe or syringe (e.g., single-chamber or multi-chamber). In certain embodiments, the vaccine is provided for use in inhalation and is provided in a pre-filled pump, nebulizer, or inhaler.
[0231] The mRNA-LNP vaccine can be administered to a subject in need in a prophylactic effective amount, i.e., an amount that provides sufficient immune protection against the target pathogen for a sufficient amount of time (e.g., one year, two years, five years, ten years, or a lifetime). Sufficient immune protection can be, for example, the prevention or alleviation of symptoms associated with pathogen infection. In some embodiments, multiple doses (e.g., two doses) of the vaccine are administered (e.g., injected) to a subject in need to achieve the desired prophylactic effect. Doses (e.g., a primary immunization dose and a booster dose) can be separated by, for example, 2 weeks, 3 weeks, 4 weeks, one month, two months, three months, four months, five months, six months, nine months, one year, two years, three years, five years, or ten years.
[0232] In some embodiments, a single dose of mRNA-LNP vaccine contains 1-50 μg of mRNA (e.g., monovalent or multivalent). For example, a single dose may contain about 2.5 μg, about 5 μg, about 7.5 μg, about 10 μg, about 12.5 μg, or about 15 μg of mRNA for intramuscular (IM) injection. In other embodiments, a multivalent single dose of LNP vaccine contains a variety of (e.g., 2, 3 or 4) LNPs (each for a different antigen), and each LNP has, for example, 2.5 μg, about 5 μg, about 7.5 μg, about 10 μg, about 12.5 μg, or about 15 μg of mRNA.
[0233] Unless otherwise defined herein, the scientific and technical terms used in conjunction with this disclosure should have the meaning commonly understood by those of ordinary skill in the art. Although methods and materials similar to or equivalent to those described herein can also be used in the practice or test of this disclosure, exemplary methods and materials are described below. In the event of a conflict, this specification including the definition shall prevail. Usually, the nomenclature and technology used in conjunction with cell and tissue culture, molecular biology, virology, immunology, microbiology, genetics, analytical chemistry, synthetic organic chemistry, medicine and pharmaceutical chemistry, and protein and nucleic acid chemistry and hybridization as described herein are those nomenclatures and technologies well known and commonly used in the art. Enzymatic reactions and purification techniques are carried out as usually realized in this area or as described herein according to the manufacturer's instructions. Further, unless the context requires otherwise, singular terms should include plural numbers, and plural terms should include singular numbers. Throughout the present specification and examples, the words "have" and "comprise" or variations such as "has / having", "comprises / comprising" should be understood to mean including the stated integer or group of integers, but not excluding any other integer or group of integers. All publications and other references mentioned herein are incorporated by reference in their entirety. Although a number of documents are cited herein, this citation does not constitute an admission that any of these documents form part of the common general knowledge in the art. As used herein, when applied to one or more values of interest, the term "about" or "approximately" refers to a value similar to the reference value. In certain embodiments, the term refers to a range of values that fall within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less in either direction (greater or less than) of the reference value, unless otherwise stated or otherwise obvious from the context. VII. Vector
[0234] On the one hand, disclosed herein is a vector comprising the mRNA compositions disclosed herein. The RNA sequence encoding the target protein (for example, the mRNA encoding the OspA protein) can be cloned into many types of vectors. For example, nucleic acid can be cloned into a vector, and the vector includes but is not limited to plasmid, phagemid, phage derivative, animal virus and cosmid. Particularly interesting vectors include expression vectors, replication vectors, probe generation vectors, sequencing vectors and vectors optimized for in vitro transcription.
[0235] In certain embodiments, the vector can be used to express mRNA in a host cell. In various embodiments, the vector is used as a template for IVT. The construction of the most preferably translated IVT mRNA suitable for therapeutic use is disclosed in detail in Sahin et al. (2014). Nat. Rev. Drug Discov. [Nature Review: Drug Discovery] 13, 759-780; Weissman (2015). Expert Rev. Vaccines [Vaccine Expert Review] 14, 265-281.
[0236] In some embodiments, the vector disclosed herein may comprise at least the following from 5' to 3': an RNA polymerase promoter; a polynucleotide sequence encoding a 5'UTR; a polynucleotide sequence encoding an ORF; a polynucleotide sequence encoding a 3'UTR; and a polynucleotide sequence encoding at least one RNA aptamer. In some embodiments, the vector disclosed herein also comprises a polynucleotide sequence encoding a poly A sequence and / or a polyadenylation signal.
[0237] A variety of RNA polymerase promoters are known in the art. In certain embodiments, the promoter can be a T7 RNA polymerase promoter. Other useful promoters include, but are not limited to, T3 and SP6 RNA polymerase promoters. The consensus nucleotide sequences for T7, T3, and SP6 promoters are known in the art.
[0238] Also disclosed herein are host cells (eg, mammalian cells, eg, human cells) comprising a vector or RNA composition disclosed herein.
[0239] The polynucleotides can be introduced into the target cells using any of a variety of different methods, e.g., commercially available methods including, but not limited to, electroporation (Amaxa Nucleofector-II (Amaxa Biosystems, Cologne, Germany)), (ECM 830 (BTX) (Harvard Instruments, Boston, Mass.) or Gene Pulser II (BioRad, Denver, Colo.), Multiporator (Eppendorf, Hamburg, Germany), cationic liposome-mediated transfection using lipofection, polymer encapsulation, peptide-mediated transfection, biolistic particle delivery systems (e.g., "gene guns") (see, e.g., Nishikawa et al. (2001). Hum Gene Ther. [Human Gene Ther.] 12(8):861-70 or TransIT-RNA transfection kit (Mirus, Madison, WI).
[0240] Chemical means for introducing polynucleotides into host cells include colloidal dispersion systems, such as macromolecular complexes, nanocapsules, microspheres, beads, and lipid-based systems (including oil-in-water emulsions, micelles, mixed micelles, and liposomes). An exemplary colloidal system used as a delivery vehicle in vitro and in vivo is a liposome (e.g., an artificial membrane vesicle).
[0241] Regardless of the method used to introduce exogenous nucleic acid into a host cell or otherwise expose the cell to an inhibitor of the disclosure, a variety of measurements can be made to confirm the presence of the mRNA sequence in the host cell. VIII. Self-replicating RNA, trans-replicating RNA, and non-replicating RNA
[0242] Self-replicating RNA:
[0243] Self-replicating (or self-amplification) RNA can be produced by using a replication element derived from, for example, an alphavirus and replacing structural viral proteins with a nucleotide sequence encoding a target protein (e.g., an antigenic prokaryotic polypeptide). Self-replicating RNA is typically a positive strand molecule that can be directly translated after being delivered to a cell, and this translation provides an RNA-dependent RNA polymerase that then produces both antisense and sense transcripts from the RNA delivered. Therefore, the RNA delivered causes multiple sub-RNAs to be produced. These sub-RNAs and colinear subgenomic transcripts can translate themselves to provide the in-situ expression of encoded antigens, or can be transcribed to provide further transcripts with the same meaning as the RNA delivered, and these transcripts are translated to provide the in-situ expression of antigens. The overall result of this transcription sequence is that the number of the replicon RNA introduced is amplified in large quantities, and therefore the encoded antigen becomes the main polypeptide product of the cell.
[0244] A suitable system for realizing self-replication in this way is to use a replicon based on alphavirus. These replicons are positive strand (sense strand) RNA, which causes the translation of replicase (or replicase-transcriptase) after being delivered to the cell. Replicase is translated into polyprotein, and this polyprotein automatically cuts to provide replication complex, and this replication complex produces the genome chain copy of the RNA delivered by the positive strand. These negative (-) strand transcripts themselves can be transcribed to produce a further copy of the positive strand parent RNA, and also produce the subgenomic transcript of the coded antigen. Therefore, the translation of the subgenomic transcript makes the infected cell in situ expressed antigen. Suitable alphavirus replicons can use the replicase from Sindbis virus (Sindbis virus), Semliki forest virus (Semliki forest virus), eastern equine encephalitis virus (eastern equine encephalitisvirus), Venezuelan equine encephalitis virus (Venezuelan equine encephalitis virus) etc. Mutant or wild-type viral sequences may be used, for example, the attenuated TC83 mutant of VEEV has been used in replicons, see the following reference: WO 2005 / 113782, which is incorporated herein by reference.
[0245] In one embodiment, each self-replicating RNA described herein encodes (i) an RNA-dependent RNA polymerase that can transcribe RNA from a self-replicating RNA molecule, and (ii) an influenza protein antigen. The polymerase can be an alphavirus replicase, for example, comprising one or more of the alphavirus proteins nsP1, nsP2, nsP3, and nsP4. Although the natural alphavirus genome also encodes structural virion proteins in addition to the non-structural replicase polyprotein, in certain embodiments, the self-replicating RNA molecule does not encode alphavirus structural proteins. Therefore, the self-replicating RNA may lead to the production of copies of its own genomic RNA in the cell, but does not lead to the production of RNA-containing virions. The inability to produce these virions means that, unlike wild-type alphaviruses, self-replicating RNA molecules cannot perpetuate themselves in an infectious form. The alphavirus structural proteins necessary for permanent existence in wild-type viruses do not exist in the self-replicating RNA of the present disclosure, and their positions are replaced by one or more genes encoding the immunogen of interest, so that the subgenomic transcripts encode immunogens, rather than alphavirus structural virion proteins. Self-replicating RNA is further described in detail in WO 2011005799, which is incorporated herein by reference.
[0246] Trans-replicating RNA:
[0247] Trans-replication (or trans-amplification) RNA has similar elements to the above-mentioned self-replication RNA. However, for trans-replication RNA, two separate RNA molecules are used. The first RNA molecule encodes the above-mentioned RNA replicase (e.g., alphavirus replicase), and the second RNA molecule encodes the target protein (e.g., antigenic prokaryotic polypeptide). RNA replicase can copy one or both of the first RNA molecule and the second RNA molecule, thereby greatly increasing the copy number of the RNA molecule encoding the target protein. Trans-replication RNA is further described in detail in WO 2017162265, which is incorporated herein by reference.
[0248] Non-replicating RNA:
[0249] Non-replicating (or non-amplifying) RNA is RNA that does not have the ability to replicate itself. IX. Pharmaceutical Compositions
[0250] The pharmaceutical compositions according to the present disclosure typically include nucleic acids, particularly RNA, more particularly mRNA, and a pharmaceutically acceptable carrier, or a pharmaceutically acceptable excipient or a pharmaceutically acceptable diluent, which makes the composition particularly suitable for therapeutic use. The phrase "pharmaceutically acceptable" as used herein refers to those compounds, materials, compositions, and / or dosage forms that are suitable for use in contact with human and animal tissues without excessive toxicity, irritation, allergic response, or other problems or complications, within the scope of reasonable medical judgment, and with a commensurate reasonable benefit / risk ratio.
[0251] The pharmaceutical composition may be, for example, an immunogenic composition, ie a composition that elicits an immune response when administered to a subject. It should be understood that the terms "immunogenic composition", "vaccine composition" and "vaccine" are used interchangeably herein and are therefore intended to have equivalent meanings.
[0252] The pharmaceutical composition of this disclosure may also include one or more other components, such as small molecule immunopotentiators (e.g., TLR agonists). The pharmaceutical composition of this disclosure may also include a delivery system for RNA, such as liposomes, oil-in-water emulsions or microparticles. In certain embodiments, the pharmaceutical composition includes lipid nanoparticles (LNP). In one embodiment, the composition includes a nucleic acid molecule encapsulated in the coding antigen in the LNP. X. Vaccination Methods
[0253] The Lyme disease vaccine disclosed herein can be administered to a subject to induce an immune response to an antigenic protein from Borrelia, such as an OspA protein expressed on the surface of Borrelia bacteria, wherein the anti-antigen antibody titer in the subject after vaccination is increased relative to the anti-antigen antibody titer in a subject not vaccinated with the Lyme disease vaccine disclosed herein, or relative to an alternative vaccine for Lyme disease. "Anti-antigen antibodies" are serum antibodies that specifically bind to an antigen.
[0254] In one aspect, the present disclosure provides a method of eliciting an immune response, preferably a humoral immune response, and / or treating or preventing Lyme disease in a subject in need thereof, the method comprising administering to the subject a Lyme disease vaccine disclosed herein.
[0255] The present disclosure also provides a Lyme disease vaccine as described herein for use in eliciting an immune response, preferably a humoral immune response, and / or treating or preventing Lyme disease in a subject in need thereof.
[0256] The present disclosure also provides for the use of the Lyme disease vaccine described herein for the manufacture of a medicament for eliciting an immune response, preferably a humoral immune response, and / or treating or preventing Lyme disease in a subject in need thereof.
[0257] In certain embodiments, the subject has similar or higher serum concentrations of anti-OspA antibodies after administration of a Lyme disease vaccine comprising an OspA recombinant protein [Recombitek, OspA fusion ST1-ST2, OspA ferritin] relative to a subject administered the Lyme disease vaccine.
[0258] The present invention includes the following embodiments.
[0259] Embodiment 1. A nucleic acid comprising an open reading frame (ORF) encoding at least one antigenic polypeptide, which antigenic polypeptide is derived from at least one Borrelia bacterium, which at least one bacterium is preferably selected from the species Borrelia burgdorferi, Borrelia afzofsky, Borrelia garinii, Borrelia bavaria, Borrelia mayoni, Borrelia sparmannii, Borrelia lusitaniai, Borrelia bisetti and / or Borrelia faresii, or any strain or isolate thereof.
[0260] Embodiment 2. The nucleic acid of embodiment 1, wherein the at least one antigenic polypeptide comprises at least one Borrelia lipoprotein.
[0261] Embodiment 3. The nucleic acid of embodiment 1 or 2, wherein the at least one antigenic polypeptide or lipoprotein is OspA or a fragment or variant thereof, preferably comprising at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90 or 100 amino acids.
[0262] Embodiment 4. The nucleic acid of any one of embodiments 1-3, wherein OspA is derived from OspA serotype (ST) 1, 2, 3, 4, 5, 6 and / or 7, preferably from serotype 1 Borrelia burgdorferi strain B31, serotype 2 Borrelia afzakii strain PKO, serotype 3 Borrelia garinii strain PBr, serotype 4 Borrelia bavariae, serotype 5 Borrelia garinii, serotype 6 Borrelia garinii, or serotype 7 Borrelia garinii.
[0263] Embodiment 5. The nucleic acid of any one of embodiments 1-4, wherein the at least one OspA polypeptide comprises an amino acid sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to any one of SEQ ID NOs: 1-7.
[0264] Embodiment 6. The nucleic acid of any one of embodiments 1-5, comprising a nucleotide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to any one of SEQ ID NOs: 10-13 and 16-19.
[0265] Embodiment 7. The nucleic acid of any one of embodiments 1-6, wherein the nucleic acid encodes at least two different OspA serotypes or fragments thereof or variants, wherein each of the at least two different OspA serotypes or fragments thereof or variants preferably comprises at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90 or 100 amino acids.
[0266] Embodiment 8. The nucleic acid of embodiment 7, wherein OspA or a fragment or variant thereof of one serotype is fused to OspA or a fragment or variant thereof of a different serotype.
[0267] Embodiment 9. The nucleic acid of embodiment 8, wherein the OspA of the different serotypes of the fusion or its fragments or variants are separated by a joint sequence, wherein the joint sequence is preferably derived from P66 or comprises an amino acid sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to SEQ ID NO:8 or SEQ ID NO:9.
[0268] Embodiment 10. The nucleic acid of any one of embodiments 1-9, wherein the nucleic acid is a non-replicating nucleic acid.
[0269] Embodiment 11. The nucleic acid of any one of embodiments 1-9, wherein the nucleic acid is a self-replicating nucleic acid or a trans-replicating nucleic acid.
[0270] Embodiment 12. The nucleic acid of any one of embodiments 1-11, wherein the nucleic acid is DNA.
[0271] Embodiment 13. The nucleic acid of any one of embodiments 1-11, wherein the nucleic acid is messenger RNA (mRNA).
[0272] Embodiment 14. The nucleic acid of embodiment 13, wherein the mRNA comprises at least one 5' cap, at least one 5' untranslated region (5'UTR), at least one 3' untranslated region (3'UTR) and / or at least one polyadenylation (poly A) sequence, wherein for example the mRNA may comprise: - at least one 5' cap, or - at least one 5'UTR, or - at least one 3'UTR, or - at least one 5'UTR and at least one 3'UTR, or - at least one poly A sequence, or - at least one 5' cap and at least one poly A sequence, or - at least one 5' cap, at least one 5' UTR, at least one 3' UTR and at least one poly A sequence.
[0273] Embodiment 15. The nucleic acid of embodiment 14, wherein the 5' cap is selected from the group consisting of: 3'-O-Me-m7G(5')ppp(5')G (ARCA cap), G(5')ppp(5')A, G(5')ppp(5')G, m7G(5')ppp(5')A, m7G(5')ppp(5')G, m7G(5')ppp(5')(2'OMeA)pG, m7G(5')ppp(5')(2'OMeA)pU and m7G(5')ppp(5')(2'OMeG)pG.
[0274] Embodiment 16. The nucleic acid of embodiment 14, wherein the 5' cap comprises:
[0275] Embodiment 17. The nucleic acid of any one of embodiments 14-16, wherein the 5'UTR is about 10 to 5,000 nucleotides in length (e.g., about 50 to 500 nucleotides in length, or at least about 10 nucleotides in length, about 20 nucleotides in length, about 30 nucleotides in length, about 40 nucleotides in length, about 50 nucleotides in length, about 100 nucleotides in length, about 150 nucleotides in length, about 200 nucleotides in length, about 250 nucleotides in length, about 300 nucleotides in length, about 350 nucleotides in length, about 400 nucleotides in length, about 450 nucleotides in length, about 500 nucleotides in length, about 550 nucleotides in length, about 600 nucleotides in length, about 650 nucleotides in length, about 700 nucleotides in length, about 750 nucleotides in length, about 800 nucleotides in length, about 850 nucleotides in length, about 900 nucleotides in length, about 950 nucleotides in length, about 1,000 nucleotides in length, about 1,500 nucleotides in length, about 2,000 nucleotides in length, about 2,500 nucleotides in length, about 3,000 nucleotides in length, about 3,500 nucleotides in length, about 4,000 nucleotides in length, about 4,500 nucleotides in length or about 5,000 nucleotides in length).
[0276] Embodiment 18. The nucleic acid of any one of embodiments 14-17, wherein the 3'UTR is 50 to 5,000 nucleotides in length or longer (e.g., 50 to 1,000 nucleotides in length or longer, or about 50 nucleotides in length, about 100 nucleotides in length, about 150 nucleotides in length, about 200 nucleotides in length, about 250 nucleotides in length, about 300 nucleotides in length, about 350 nucleotides in length, about 400 nucleotides in length, about 450 nucleotides in length, about 500 nucleotides in length, about 550 nucleotides in length, about 60 0 nucleotides in length, about 650 nucleotides in length, about 700 nucleotides in length, about 750 nucleotides in length, about 800 nucleotides in length, about 850 nucleotides in length, about 900 nucleotides in length, about 950 nucleotides in length, about 1,000 nucleotides in length, about 1,500 nucleotides in length, about 2,000 nucleotides in length, about 2,500 nucleotides in length, about 3,000 nucleotides in length, about 3,500 nucleotides in length, about 4,000 nucleotides in length, about 4,500 nucleotides in length, or about 5,000 nucleotides in length).
[0277] Embodiment 19. The nucleic acid of any one of embodiments 14-18, wherein the 5' and / or 3' UTR is derived from a gene different from the gene encoded by the mRNA transcript (ie, the UTR is a heterologous UTR).
[0278] Embodiment 20. The nucleic acid of any one of embodiments 14-19, wherein the 5' and / or 3' UTR sequence is derived from a stable mRNA (eg, globin, actin, GAPDH, tubulin, histone, or citric acid cycle enzyme) to increase the stability of the mRNA.
[0279] Embodiment 21. The nucleic acid of any one of embodiments 14-19, wherein the 5'UTR is derived from the CMV immediate early 1 (IE1) gene.
[0280] Embodiment 22. The nucleic acid of any one of embodiments 14-19, wherein the 5'UTR comprises the sequence GGGAUCCUACC (SEQ ID NO: 20).
[0281] Embodiment 23. The nucleic acid of any one of embodiments 14-19, wherein the 5'UTR is derived from the 5'UTR of a TOP gene.
[0282] Embodiment 24. The nucleic acid of any one of embodiments 14-19, wherein the 5'UTR is derived from the ribosomal protein large 32 (L32) gene.
[0283] Embodiment 25. The nucleic acid of any one of embodiments 14-19, wherein the 5'UTR is derived from the 5'UTR of the hydroxysteroid (17-b) dehydrogenase 4 gene (HSD17B4).
[0284] Embodiment 26. The nucleic acid of any one of embodiments 14-19, wherein the 5'UTR is derived from the 5'UTR of the ATP5A1 gene.
[0285] Embodiment 27. The nucleic acid of any one of embodiments 14-19, wherein an internal ribosome entry site (IRES) is used instead of the 5'UTR.
[0286] Embodiment 28. The nucleic acid of any one of embodiments 14-19, wherein the 5'UTR comprises the nucleic acid sequence shown in SEQ ID NO:14.
[0287] Embodiment 29. The nucleic acid of any one of embodiments 14-28, wherein the 3'UTR comprises the nucleic acid sequence shown in SEQ ID NO:15.
[0288] Embodiment 30. The nucleic acid of any one of embodiments 14-29, wherein the at least one polyadenylation (poly A) sequence comprises about 10 to about 500 adenosine nucleotides, about 10 to about 200 adenosine nucleotides, about 40 to about 200 adenosine nucleotides, or about 40 to about 150 adenosine nucleotides.
[0289] Embodiment 31. The nucleic acid of any one of embodiments 14-30, wherein the at least one polyadenylation (poly A) sequence comprises at least about 10, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450 or 500 adenosine nucleotides.
[0290] Embodiment 32. The nucleic acid of any one of embodiments 14-31, wherein the at least one polyadenylation (poly A) sequence comprises the sequence AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGCAUAUGACUAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAA (SEQ ID NO: 21).
[0291] Embodiment 33. The nucleic acid of any one of embodiments 30-32, wherein the 5'UTR is about 10 to 5,000 nucleotides in length (e.g., about 50 to 500 nucleotides in length, or at least about 10 nucleotides in length, about 20 nucleotides in length, about 30 nucleotides in length, about 40 nucleotides in length, about 50 nucleotides in length, about 100 nucleotides in length, about 150 nucleotides in length, about 200 nucleotides in length, about 250 nucleotides in length, about 300 nucleotides in length, about 350 nucleotides in length, about 400 nucleotides in length, about 450 nucleotides in length, about 50 ... a length of about 550 nucleotides, a length of about 600 nucleotides, a length of about 650 nucleotides, a length of about 700 nucleotides, a length of about 750 nucleotides, a length of about 800 nucleotides, a length of about 850 nucleotides, a length of about 900 nucleotides, a length of about 950 nucleotides, a length of about 1,000 nucleotides, a length of about 1,500 nucleotides, a length of about 2,000 nucleotides, a length of about 2,500 nucleotides, a length of about 3,000 nucleotides, a length of about 3,500 nucleotides, a length of about 4,000 nucleotides, a length of about 4,500 nucleotides, or a length of about 5,000 nucleotides).
[0292] Embodiment 34. The nucleic acid of any one of embodiments 30-33, wherein the 3'UTR is 50 to 5,000 nucleotides in length or longer (e.g., 50 to 1,000 nucleotides in length or longer, or about 50 nucleotides in length, about 100 nucleotides in length, about 150 nucleotides in length, about 200 nucleotides in length, about 250 nucleotides in length, about 300 nucleotides in length, about 350 nucleotides in length, about 400 nucleotides in length, about 450 nucleotides in length, about 500 nucleotides in length, about 550 nucleotides in length, about 60 0 nucleotides in length, about 650 nucleotides in length, about 700 nucleotides in length, about 750 nucleotides in length, about 800 nucleotides in length, about 850 nucleotides in length, about 900 nucleotides in length, about 950 nucleotides in length, about 1,000 nucleotides in length, about 1,500 nucleotides in length, about 2,000 nucleotides in length, about 2,500 nucleotides in length, about 3,000 nucleotides in length, about 3,500 nucleotides in length, about 4,000 nucleotides in length, about 4,500 nucleotides in length, or about 5,000 nucleotides in length).
[0293] Embodiment 35. The nucleic acid of any one of embodiments 30-34, wherein the 5' and / or 3' UTR is derived from a gene different from the gene encoded by the mRNA transcript (ie, the UTR is a heterologous UTR).
[0294] Embodiment 36. The nucleic acid of any one of embodiments 30-35, wherein the 5' and / or 3' UTR sequence is derived from a stable mRNA (eg, globin, actin, GAPDH, tubulin, histone, or citric acid cycle enzyme) to increase the stability of the mRNA.
[0295] Embodiment 37. The nucleic acid of any one of embodiments 30-35, wherein the 5'UTR is derived from the CMV immediate early 1 (IE1) gene.
[0296] Embodiment 38. The nucleic acid of any one of embodiments 30-35, wherein the 5'UTR comprises the sequence GGGAUCCUACC (SEQ ID NO: 20).
[0297] Embodiment 39. The nucleic acid of any one of embodiments 30-35, wherein the 5'UTR is derived from the 5'UTR of a TOP gene.
[0298] Embodiment 40. The nucleic acid of any one of embodiments 30-35, wherein the 5'UTR is derived from a ribosomal protein large 32 (L32) gene.
[0299] Embodiment 41. The nucleic acid of any one of embodiments 30-35, wherein the 5'UTR is derived from the 5'UTR of the hydroxysteroid (17-b) dehydrogenase 4 gene (HSD17B4).
[0300] Embodiment 42. The nucleic acid of any one of embodiments 30-35, wherein the 5'UTR is derived from the 5'UTR of the ATP5A1 gene.
[0301] Embodiment 43. The nucleic acid of any one of embodiments 30-35, wherein an internal ribosome entry site (IRES) is used instead of the 5'UTR.
[0302] Embodiment 44. The nucleic acid of any one of embodiments 30-35, wherein the 5'UTR comprises the nucleic acid sequence shown in SEQ ID NO:14.
[0303] Embodiment 45. The nucleic acid of any one of embodiments 30-35, wherein the 3'UTR comprises the nucleic acid sequence shown in SEQ ID NO:15.
[0304] Embodiment 46. The nucleic acid of any one of embodiments 13-45, wherein the mRNA comprises at least the following structural elements: (i) a 5' cap having the following structure: (ii) a 5' untranslated region (5'UTR) having the nucleic acid sequence of SEQ ID NO: 14; (iii) at least one OspA open reading frame having the nucleic acid sequence of any one of SEQ ID NOs: 16-19; (iv) a 3' untranslated region (3'UTR) having the nucleic acid sequence of SEQ ID NO: 15; and (v) Poly A tail.
[0305] Embodiment 47. A nucleic acid, wherein the nucleic acid is an mRNA, the mRNA comprising an open reading frame (ORF) encoding at least one antigenic polypeptide derived from at least one Borrelia bacterium, wherein the mRNA comprises at least the following structural elements: (i) a 5' cap having the following structure: (ii) a 5' untranslated region (5'UTR) having the nucleic acid sequence of SEQ ID NO: 14; (iii) at least one OspA open reading frame having the nucleic acid sequence of any one of SEQ ID NOs: 16-19; (iv) a 3' untranslated region (3'UTR) having the nucleic acid sequence of SEQ ID NO: 15; and (v) poly A tail; Wherein the mRNA is formulated in a lipid nanoparticle (LNP), the lipid nanoparticle comprising: The molar ratio is 40% cKK-E10, The molar ratio is 1.5% DMG-PEG2000, The molar ratio is 28.5% cholesterol, and 30% DOPE by molar ratio; or OF-02 with a molar ratio of 40%; DMG-PEG2000 with a molar ratio of 1.5%; 28.5% by molar ratio of cholesterol; and 30% DOPE by molar ratio; or GL-HEPES-E3-E10-DS-3-E18-1 at a molar ratio of 40%; DMG-PEG2000 with a molar ratio of 1.5%; 28.5% by molar ratio of cholesterol; and 30% DOPE by molar ratio; or GL-HEPES-E3-E12-DS-4-E10 at a molar ratio of 40%; DMG-PEG2000 with a molar ratio of 1.5%; 28.5% by molar ratio of cholesterol; and 30% DOPE by molar ratio; or GL-HEPES-E3-E12-DS-3-E14 at a molar ratio of 40%; DMG-PEG2000 with a molar ratio of 1.5%; 28.5% by molar ratio of cholesterol; and 30% DOPE by molar ratio; or 50% molar ratio of 8-{(2-hydroxyethyl)[6-oxo-6-(undecyloxy)hexyl]amino}octanoic acid 9-heptadecyl ester (SM-102); 1,2-distearoyl-sn-glycero-3-phosphorylcholine (DSPC) at a molar ratio of 10%; 38.5% by molar ratio of cholesterol; and 1.5% molar ratio of 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (DMG-PEG2000); or (4-Hydroxybutyl)azanediyl]bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315) at a molar ratio of 46.3%; 1,2-distearoyl-sn-glycero-3-phosphorylcholine (DSPC) at a molar ratio of 9.4%; 42.7% by molar ratio of cholesterol; and 1.6% molar ratio of 2-[(polyethylene glycol)-2000]-N,N-di-tetradecyl acetamide (ALC-0159); or (4-Hydroxybutyl)azanediyl]bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315) at a molar ratio of 47.4%; 1,2-distearoyl-sn-glycero-3-phosphorylcholine (DSPC) at a molar ratio of 10%; 40.9% by molar ratio of cholesterol; and 2-[(Polyethylene glycol)-2000]-N,N-di-tetradecylacetamide (ALC-0159) at a molar ratio of 1.7%.
[0306] Embodiment 48. The nucleic acid of any one of embodiments 1-47, wherein the nucleic acid comprises at least one chemical modification.
[0307] Embodiment 49. The nucleic acid of embodiment 48, wherein at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95% or 100% of the uracil nucleotides are chemically modified.
[0308] Embodiment 50. The nucleic acid of embodiment 48 or 49, wherein the chemical modification is selected from the group consisting of pseudouridine, N1-methylpseudouridine, 2-thiouridine, 4'-thiouridine, 5-methylcytidine, 2-thiol-1-methyl-1-deaza-pseudouridine, 2-thiol-1-methyl-pseudouridine, 2-thiol-5-aza-uridine, 2-thiol-dihydropseudouridine, 2-thiol-dihydrouridine, 2-thiol-pseudouridine, 4-methoxy-2-thiol-pseudouridine, 4-methoxy-pseudouridine, 4-thiol-1-methyl-pseudouridine, 4-thiol-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methyluridine, 5-methyluridine, 5-methoxyuridine and 2'-O-methyluridine.
[0309] Embodiment 51. The nucleic acid of any one of embodiments 48-50, wherein the chemical modification is selected from the group consisting of pseudouridine, N1-methylpseudouridine, 5-methylcytidine, 5-methoxyuridine, and combinations thereof.
[0310] Embodiment 52. The nucleic acid of any one of embodiments 48-51, wherein the chemical modification is N1-methylpseudouridine.
[0311] Embodiment 53. A composition comprising at least one nucleic acid as described in any one of embodiments 1-52.
[0312] Embodiment 54. The composition of embodiment 53, wherein the nucleic acid is formulated in a non-viral delivery system.
[0313] Embodiment 55. The composition of embodiment 53 or 54, comprising lipid nanoparticles (LNP).
[0314] Embodiment 56. The composition of embodiment 55, wherein the nucleic acid is encapsulated in the LNP.
[0315] Embodiment 57. A composition as described in embodiment 55 or 56, wherein the LNP comprises at least one cationic lipid, wherein the cationic lipid may be biodegradable or may not be biodegradable, cleavable or not cleavable, and wherein the cationic lipid is preferably selected from the group consisting of: cKK-E10; OF-02; [(6Z,9Z,28Z,31Z)-triacontane-6,9,28,31-tetraen-19-yl] 4-(dimethylamino)butyrate (D-Lin-MC3-DMA); 2,2-Dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA); 1,2-Dilinoleyloxy-N,N-dimethyl 9-((4-(dimethylamino)butyryl)oxy)heptadecanedioate (L319); 8-{(2-hydroxyethyl)[6-oxo-6-(undecyloxy)hexyl]amino}octanoic acid 9-heptadecanedioate (SM-102); [(4-hydroxybutyl)azanediyl]di(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315); [3-(dimethylamino)-2-[(Z)-octadec-9-enoyl]oxypropyl](Z)-octadec-9-enoate (DODAP); 2,5-bis(3-aminopropylamino)-N-[2-[di(heptadecanyl)amino] [(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptane-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3-yl] N-[2-(dimethylamino)ethyl]carbamate (DC-Chol); tetrakis(8-methylnonyl) 3,3′,3″,3″′-(((methylazanediyl)bis(propane-3,1-diyl))bis(azanetriyl))tetrapropionate (306Oi10); (2-(dioctylammonium)ethyl)decyl phosphate (9A1P9 ); 5,5-di((Z)-heptadeca-8-en-1-yl)-1-(3-(pyrrolidin-1-yl)propyl)-2,5-dihydro-1H-imidazole-2-carboxylic acid ethyl ester (A2-Iso5-2DC18); bis(2-(dodecyldisulfanyl)ethyl)3,3'-((3-methyl-9-oxo-10-oxa-13,14-dithia-3,6-diazacosyl)azanediyl)dipropionate (BAME-O16B); 1,1'-((2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl)(2-hydroxydodecyl)amino)ethyl)piperazin-1-yl)ethyl)azanediyl)bis(dodecan-2-ol) (C12-200);3,6-Bis(4-(bis(2-hydroxydodecyl)amino)butyl)piperazine-2,5-dione (cKK-E12); Hexa(octan-3-yl) 9,9′,9″,9″′,9″″,9″′″-((((benzene-1,3,5-tricarbonyl)tri(azanediyl))tri(propane-3,1-diyl))tri(azanetriyl))hexanonanoate (FTT5); (((3,6-dioxopiperazine-2,5-diyl)bis(butane-4,1-diyl))bis(azanetriyl))tetra(ethane-2,1-diyl)(9Z,9′Z,9″Z,9″′Z,12Z,12′Z,12″Z,12″′Z)-tetra(octadec-9,12-dienoate) (OF-Deg-Lin); TT3; N; 1 ,N 3 ,N 5 -Tris(3-(didodecylamino)propyl)benzene-1,3,5-tricarboxamide; N1-[2-((1S)-1-[(3-aminopropyl)amino]-4-[bis(3-aminopropyl)amino]butylcarboxamido)ethyl]-3,4-di[oleyloxy]-benzamide (MVL5); 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoic acid heptadecan-9-yl ester (lipid 5); GL-HEPES-E3-E10-DS-3-E18-1; GL-HEPES-E3-E12-DS-4-E10; GL-HEPES-E3-E12-DS-3-E14; and combinations thereof.
[0316] Embodiment 58. The composition of embodiment 57, wherein the LNP further comprises a polyethylene glycol (PEG)-conjugated (PEGylated) lipid, a cholesterol-based lipid, and / or a helper lipid.
[0317] Embodiment 59. A composition as described in any of Embodiments 55-58, wherein the LNP comprises: - a cationic lipid in a molar ratio of 35% to 55%; - a polyethylene glycol (PEG)-conjugated (PEGylated) lipid in a molar ratio of 0.25% to 2.75%; - a cholesterol-based lipid in a molar ratio of 20% to 45%; and - an auxiliary lipid in a molar ratio of 5% to 35%, wherein all molar ratios are relative to the total lipid content of the LNP.
[0318] Embodiment 60. A composition as described in any of embodiments 55-59, wherein the LNP comprises: - a cationic lipid at a molar ratio of 40%; - a PEGylated lipid at a molar ratio of 1.5%; - a cholesterol-based lipid at a molar ratio of 28.5%; and - a helper lipid at a molar ratio of 30%.
[0319] Embodiment 61. A composition as described in any of Embodiments 55-60, wherein the LNP comprises: - a cationic lipid at a molar ratio of 45% to 50%; - a PEGylated lipid at a molar ratio of 1.5% to 1.7%; - a cholesterol-based lipid at a molar ratio of 38% to 43%; and - a helper lipid at a molar ratio of 9% to 10%.
[0320] Embodiment 62. The composition of any one of embodiments 58-61, wherein the PEGylated lipid is dimyristoyl-PEG2000 (DMG-PEG2000) or 2-[(polyethylene glycol)-2000]-N,N-ditetradecanoylacetamide (ALC-0159).
[0321] Embodiment 63. The composition of any one of embodiments 58-62, wherein the cholesterol-based lipid is cholesterol.
[0322] Embodiment 64. The composition of any one of embodiments 58-63, wherein the helper lipid is 1,2-dioleoyl-SN-glycero-3-phosphoethanolamine (DOPE) or 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC).
[0323] Embodiment 65. A composition as described in any of Embodiments 55-64, wherein the LNP comprises: - a cationic lipid selected from the group consisting of OF-02, cKK-E10, GL-HEPES-E3-E10-DS-3-E18-1, GL-HEPES-E3-E12-DS-4-E10 and GL-HEPES-E3-E12-DS-3-E14 at a molar ratio of 40%; - DMG-PEG2000 at a molar ratio of 1.5%; - cholesterol at a molar ratio of 28.5%; and - DOPE at a molar ratio of 30%.
[0324] Embodiment 66. A composition as described in any of embodiments 55-65, wherein the LNP comprises: - SM-102 at a molar ratio of 50%; - DMG-PEG2000 at a molar ratio of 1.5%; - cholesterol at a molar ratio of 38.5%; and - DSPC at a molar ratio of 10%.
[0325] Embodiment 67. A composition as described in any of embodiments 55-65, wherein the LNP comprises: - ALC-0315 at a molar ratio of 46.3%; - ALC-0159 at a molar ratio of 1.6%; - cholesterol at a molar ratio of 42.7%; and - DSPC at a molar ratio of 9.4%.
[0326] Embodiment 68. A composition as described in any of embodiments 55-65, wherein the LNP comprises: - ALC-0315 at a molar ratio of 47.4%; - ALC-0159 at a molar ratio of 1.7%; - cholesterol at a molar ratio of 40.9%; and - DSPC at a molar ratio of 10%.
[0327] Embodiment 69. The composition of any one of embodiments 55-68, wherein the average diameter of the LNP is 30 nm to 200 nm.
[0328] Embodiment 70. The composition of any one of embodiments 55-68, wherein the average diameter of the LNP is 80 nm to 150 nm.
[0329] Embodiment 71. The composition of any one of embodiments 55-70, comprising 1 mg / mL to 10 mg / mL of the LNP.
[0330] Embodiment 72. A composition as described in any of embodiments 55-71, wherein the LNP comprises 1 to 20 nucleic acid molecules, preferably mRNA molecules.
[0331] Embodiment 73. The composition of any one of embodiments 53-72, formulated for intramuscular, intranasal, intravenous, subcutaneous or intradermal administration.
[0332] Embodiment 74. The composition of any one of embodiments 53-73, wherein the composition comprises phosphate buffered saline.
[0333] Embodiment 75. The composition of any one of embodiments 53-74, wherein the composition is a pharmaceutical composition, such as an immunogenic composition or a vaccine, in particular a Lyme disease vaccine.
[0334] Embodiment 76. The nucleic acid as described in any one of Embodiments 1-52 or the composition as described in any one of Embodiments 53-75 is used to induce an immune response, preferably a humoral immune response, and / or to treat or prevent Lyme disease in a subject in need thereof, wherein the subject preferably has a higher serum concentration of anti-OspA antibodies after administration of the nucleic acid or composition relative to a subject administered a Lyme disease vaccine comprising an OspA recombinant protein vaccine, and / or wherein preferably the subject is a mammal, more preferably a human, dog, cat, llama, cattle, sheep, goat, horse, rodent, mouse, rat, rabbit, monkey, primate or pig, even more preferably a human.
[0335] Embodiment 77. A method for eliciting an immune response, preferably a humoral immune response, and / or treating or preventing Lyme disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a nucleic acid as described in any one of Embodiments 1-52 or a composition as described in any one of Embodiments 53-75, optionally intramuscularly, intranasally, intravenously, subcutaneously or intradermally, wherein the subject preferably has a higher serum concentration of anti-OspA antibodies after administration of the nucleic acid or composition relative to a subject administered a Lyme disease vaccine comprising an OspA recombinant protein vaccine, and / or wherein preferably the subject is a mammal, more preferably a human, dog, cat, llama, cattle, sheep, goat, horse, rodent, mouse, rat, rabbit, monkey, primate or pig, even more preferably a human.
[0336] Embodiment 78. Use of a nucleic acid as described in any of Embodiments 1-52 or a composition as described in any of Embodiments 53-75 in the following aspects: for the manufacture of a medicament for eliciting an immune response, preferably a humoral immune response, and / or treating or preventing Lyme disease in a subject in need thereof, wherein the subject preferably has a higher serum concentration of anti-OspA antibodies after administration of the nucleic acid or composition relative to a subject administered a Lyme disease vaccine comprising an OspA recombinant protein vaccine, and / or wherein preferably the subject is a mammal, more preferably a human, dog, cat, llama, cattle, sheep, goat, horse, rodent, mouse, rat, rabbit, monkey, primate or pig, even more preferably a human.
[0337] In order to better understand the present disclosure, the following examples are described. These examples are for illustrative purposes only and are not to be construed as limiting the scope of the present disclosure in any way. Examples
[0338] The foregoing description of the particular embodiments will disclose the general nature of the present disclosure so fully that others can easily modify and / or adjust such particular embodiments for a variety of applications by applying knowledge within the technical scope of the art without undue experimentation and without departing from the overall concept of the present disclosure. Therefore, based on the teachings and guidance given herein, such adjustments and modifications are intended to be included in the meaning and range of equivalents of the disclosed embodiments. It should be understood that the terms or terms herein are for the purpose of description rather than limitation, and therefore the terms or terms of this specification will be interpreted by those skilled in the art based on the teachings and guidance. Example 1: Materials and Methods
[0339] mRNA-OspA production
[0340] mRNA was generated as previously published (Kalnin et al. (2021), NPJ Vaccines [NPJ vaccine] 6 (1): 61 and WO 2021226436). Briefly, mRNA containing the coding sequence of OspA ST1 or ST2 was synthesized using unmodified nucleotides by in vitro transcription using RNA polymerase and a plasmid DNA template encoding the desired gene. The purified precursor mRNA was further reacted by enzymatic addition of a 5' cap structure (cap 1) and a 3' poly (A) tail of approximately 200 nucleotides in length as determined by gel electrophoresis.
[0341] To prepare mRNA / lipid nanoparticle (LNP) formulations, an ethanolic solution of a mixture of lipids (cationic / ionizable lipids, phosphatidylethanolamine, cholesterol, and polyethylene glycol lipids) at a fixed lipid to mRNA ratio is combined with an aqueous buffer solution of the target mRNA under controlled conditions at acidic pH to produce a uniform LNP suspension. After ultrafiltration and diafiltration into a suitable dilution system, the resulting nanoparticle suspension is diluted to the final concentration, filtered, and stored frozen at -80°C until use.
[0342] Generation of antigens used as benchmark comparators
[0343] OspA ferritin ST1 and ST2 antigens were generated by Sanofi Breakthrough Lab, Cambridge, MA, USA, according to previously published materials and methods (Kamp et al. (2020), NPJ Vaccines 5(1):33).
[0344] For OspA fusion ST1-ST2, internal plasmid pSP401+LPP-chimer OspA1-OspA2 (this internal plasmid allows OspA to fuse the expression of ST1-ST2 C-terminal domain) is introduced into Escherichia coli expression strain C43-(DE3) (Lucigen company (Lucigen)).After growing in 37 ℃ rich medium for 2 to 3 hours, by adding inducing agent induction target protein expression, and after induction, stop cultivating 3 hours.After processing bacterial mass, on Coomassie blue stained SDS-Page gel or by using specific antibody western blotting, protein visualization is made.Enlarge under optimal expression conditions, to produce enough biomass required for purification.Bacterial mass is treated with lysozyme to extract membrane protein.Then extract OspA1-OspA2 fusion protein with urea 2M+Triton X114 2%. After three incubation-centrifugation steps at 37°C, the lower phase was collected and subjected to Q Sepharose chromatography in the presence of Zwittergent 3.14 detergent (0.5%). The fraction eluted with 400 mM NaCl was subjected to ceramic hydroxyapatite chromatography. The OspA1-OspA2 fusion protein was eluted with a buffer of Tween 0.05% PO4NaNa2 (180 mM, pH 6,7) and replaced with PBS + Tween 20 0.05% (pH 7.3) as the final buffer.
[0345] Antigens and mouse immunization
[0346] OF-1 mice (Charles River Laboratories) were randomly divided into immunization groups, 8 mice in each group. Four different doses of mRNA-OspA-LNP (50 μL) were intramuscularly administered at day 0 (D0) (dose 1) and day 21 (D21) (dose 2): 0.2 μg, 1 μg, 5 μg or 10 μg. Serum was collected at baseline (D0), day 20 (D20) and day 35 (D35).
[0347] Two mRNA-OspA sequences were tested: mRNA-OspA-ST1-native and mRNA-OspA-ST2-native.
[0348] The mRNA formulations were compared to negative control LNP alone and to the benchmark Lyme canine vaccine at 1 μg / dose (50 μL). (Merial) for comparison.
[0349] OspA-specific IgG ELISA
[0350] The antibody reaction of mouse is measured by ELISA.In brief, 384-well microplate (PerkinElmer (PerkinElmer) #6007509) is coated with 1 μ g / mL of OspA-His of the mensuration serotype (ST1 or ST2) diluted in PBS, and incubated overnight at 4 ℃.OspA-His is removed, and the plate is blocked with 5% skim milk dissolved in PBS-tween.After removing the blocking reagent, primary serum sample is added after serial dilution 2 times in 1% skim milk PBS-tween.After incubating 1.5 hours with primary serum sample at room temperature, the plate is washed with PBS-tween, and incubated 1.5 hours with goat anti-mouse IgG-HRP (Jackson Laboratory (Jackson) 115-036-062) at room temperature.Suck out and wash secondary antibody, plate is incubated with TMB substrate (TEBU-TMB100-1000), then equal volume of stop solution (HCl 1N) is added. Absorbance was measured at 450nm-650nm. OspA specific IgG titers were quantified by internal anti-OspA mouse serum reference. The titer of this reference was previously calculated as the reciprocal of the dilution to obtain an OD of 1.
[0351] OspA protein encoding mRNA
[0352] The causative agent of Lyme disease is Borrelia bacterium.Four species of Borrelia cause most human diseases: Borrelia burgdorferi, Borrelia afforiensis, Borrelia garinii and Borrelia bavariae.Each Borrelia species has the surface expression of outer surface protein A (OspA), and seven kinds of OspA serotypes (ST1-ST7) are popular especially in the U.S. and Europe, and wherein ST1 accounts for 98% of U.S. OspA serotype, and ST2 accounts for more than 50% of European OspA serotype.For this reason, the mRNA expressing OspA ST1 or ST2 has been designed.
[0353] Use OspA native sequence.Each OspA peptide sequence listed below lacks N-terminal methionine, which is typically removed in eukaryotic cells.In certain embodiments, the amino acid sequence shown in any one of SEQ ID NO:1-7 further comprises N-terminal methionine amino acid.
[0354] Each nucleic acid listed in Table 3 corresponds to an mRNA sequence. The corresponding DNA sequence can be used as a template to produce mRNA by in vitro transcription. Except that the U nucleotides in the mRNA sequence are replaced by T nucleotides, the DNA sequence is identical to the mRNA sequence.
[0355] The amino acid sequence and nucleic acid sequence of the OspA protein and the nucleic acid sequences encoding them are shown in Tables 2 and 3 below (as well as the amino acid sequence of the linker and the nucleic acid sequences of the 5'UTR and 3'UTR).
[0356] Table 3 - Amino acid sequences of OspA proteins and linkers
[0357] Table 4 - mRNA sequences of OspA, 5'UTR and 3'UTR Example 2: Immunogenicity of mRNA encoding OspA protein in mice
[0358] As described in Example 1 above, the relative immunogenicity of various mRNAs expressing OspA was tested in mice by measuring IgG titers against OspA. Each mRNA was encapsulated into LNPs consisting of 40% cationic lipid cKK-E10, 30% phospholipid DOPE, 1.5% PEGylated lipid DMGPEG2000, and 28.5% cholesterol. Alternatively, the LNP lipids can be expressed as the following ratios, wherein cationic lipid: PEGylated lipid: cholesterol: phospholipid is 40:1.5:28.5:30.
[0359] Each LNP-mRNA composition was administered to mice at a dose of 0.2 μg, 1 μg, 5 μg or 10 μg. A total of 4 groups of 8 mice were used.
[0360] Three benchmark compositions were used: OspA fusion with AlOOH adjuvant ("OspA fusion ST1-ST2") (2 μg (1 μg per serotype) / dose); Lyme disease canine vaccine (Merial) (1 μg dose), and OspA ferritin fusion with AF03 adjuvant (ST1 or ST2) (1.7 μg (of which 1 μg OspA + 0.7 μg ferritin) / dose). OspA ferritin fusion is further described in US20210017238 A1, which is incorporated herein by reference.
[0361] As a negative control, LNPs without mRNA were administered to mice.
[0362] like Figure 1A As shown, anti-OspA ST1 IgG titers increased after the first dose (day 20).
[0363] like Figure 1B As shown, anti-OspA ST1 IgG titers further increased after the second dose (day 35).
[0364] Non-specific IgG titers induced by the LNP negative control alone remained low (not shown).
[0365] like Figure 2A As shown, anti-OspA ST2 IgG titers increased after the first dose (day 20).
[0366] like Figure 2B As shown, anti-OspA ST2 IgG titers further increased after the second dose (day 35).
[0367] Mouse study conclusions:
[0368] mRNA encoding OspA ST1 and ST2 was immunogenic and induced potent anti-OspA IgG titers in mice after the first and second doses.
[0369] A dose effect was observed (ie, IgG titers increased with increasing doses).
[0370] The mRNA encoding OspA ST1 induced higher homologous IgG titers than the mRNA encoding OspA ST2.
[0371] IgG titers induced by mRNA-OspA ST1 were equal to or higher than those induced by the benchmark OspA fusions ST1-ST2 and Recombitek (ST1).
[0372] Other embodiments of the disclosure will be apparent to those skilled in the art from consideration of the specification and practice disclosed herein. It is intended that the specification and examples be considered exemplary only, with the following claims indicating the true scope and spirit of the disclosure.
[0373] All patents and publications cited herein are incorporated by reference in their entirety.
Claims
1. A Lyme disease vaccine comprising a messenger RNA (mRNA) comprising an open reading frame (ORF) encoding at least one antigenic polypeptide derived from at least one Borrelia bacterium.
2. The Lyme disease vaccine of claim 1, wherein the mRNA is formulated in lipid nanoparticles (LNPs).
3. The Lyme disease vaccine of claim 1 or 2, wherein the mRNA is a non-replicating mRNA.
4. The Lyme disease vaccine of any one of claims 1-3, wherein the mRNA comprises at least one chemical modification.
5. The Lyme disease vaccine of any one of claims 1-4, wherein the Borrelia bacterium is selected from the species Borrelia burgdorferi, Borrelia afforei, Borrelia garinii, Borrelia bavariansis, Borrelia mayoni, Borrelia sparmannii, Borrelia lusitaniae, Borrelia bisettii and / or Borrelia faresii, or any strain or isolate thereof.
6. The Lyme disease vaccine of any one of claims 1-5, wherein the at least one antigenic polypeptide comprises at least one Borrelia lipoprotein.
7. The Lyme disease vaccine of any one of claims 1-6, wherein the at least one antigenic polypeptide or lipoprotein is OspA or a fragment or variant thereof.
8. The Lyme disease vaccine of claim 7, wherein the OspA or a fragment or variant thereof comprises at least 5 amino acids.
9. A Lyme disease vaccine as claimed in claim 7 or 8, wherein the OspA or a fragment or variant thereof is derived from OspA serotype (ST) 1, 2, 3, 4, 5, 6 and / or 7.
10. A Lyme disease vaccine as described in any one of claims 7-9, wherein the OspA or a fragment or variant thereof is derived from serotype 1 Borrelia burgdorferi strain B31, serotype 2 Borrelia afzofsky strain PKO, serotype 3 Borrelia garinii strain PBr, serotype 4 Borrelia bavariae, serotype 5 Borrelia garinii, serotype 6 Borrelia garinii, or serotype 7 Borrelia garinii.
11. The Lyme disease vaccine of any one of claims 7-10, wherein the at least one OspA polypeptide comprises an amino acid sequence at least 85% identical to any one of SEQ ID NOs: 1-7.
12. The Lyme disease vaccine of any one of claims 1-11, wherein the mRNA comprises a nucleotide sequence at least 85% identical to any one of SEQ ID NOs: 10-13 and 16-19.
13. The Lyme disease vaccine of any one of claims 1-12, wherein the mRNA encodes at least two different OspA serotypes or fragments or variants thereof.
14. A Lyme disease vaccine as claimed in claim 13, wherein an OspA or fragment thereof of one serotype preferably comprising at least 5 amino acids is fused to an OspA or fragment thereof of a different serotype preferably comprising at least 5 amino acids.
15. The Lyme disease vaccine of claim 14, wherein the fused OspA of different serotypes or fragments or variants thereof are separated by a linker sequence.
16. The Lyme disease vaccine of claim 15, wherein the linker sequence is derived from P66 or comprises an amino acid sequence having at least 85% identity to SEQ ID NO:8 or SEQ ID NO:
9.
17. The Lyme disease vaccine of any one of claims 1-16, wherein the mRNA comprises at least one chemical modification.
18. The Lyme disease vaccine of claim 17, wherein the chemical modification is selected from the group consisting of pseudouridine, N1-methylpseudouridine, 2-thiouridine, 4'-thiouridine, 5-methylcytidine, 2-thiol-1-methyl-1-deaza-pseudouridine, 2-thiol-1-methyl-pseudouridine, 2-thiol-5-aza-uridine, 2-thiol-dihydropseudouridine, 2-thiol-dihydrouridine, 2-thiol-pseudouridine, 4-methoxy-2-thiol-pseudouridine, 4-methoxy-pseudouridine, 4-thiol-1-methyl-pseudouridine, 4-thiol-pseudouridine, 5-aza-uridine, dihydropseudouridine, 5-methyluridine, 5-methyluridine, 5-methoxyuridine and 2'-O-methyluridine.
19. The Lyme disease vaccine of claim 17 or 18, wherein the chemical modification is selected from the group consisting of pseudouridine, N1-methylpseudouridine, 5-methylcytidine, 5-methoxyuridine, and combinations thereof.
20. The Lyme disease vaccine of any one of claims 17-19, wherein the chemical modification is N1-methylpseudouridine.
21. The Lyme disease vaccine of any one of claims 1-20, wherein the mRNA is formulated in lipid nanoparticles (LNPs).
22. The Lyme disease vaccine of claim 21, wherein the LNP comprises at least one cationic lipid.
23. The Lyme disease vaccine of claim 22, wherein the cationic lipid is biodegradable.
24. The Lyme disease vaccine of claim 22, wherein the cationic lipid is not biodegradable.
25. The Lyme disease vaccine of any one of claims 22-24, wherein the cationic lipid is cleavable.
26. The Lyme disease vaccine of any one of claims 22-24, wherein the cationic lipid is not cleavable.
27. The Lyme disease vaccine of any one of claims 22-26, wherein the cationic lipid is selected from the group consisting of: ML7 / OF-02; cKK-E10; GL-HEPES-E3-E10-DS-3-E18-1; GL-HEPES-E3-E12-DS-4-E10; GL-HEPES-E3-E12-DS-3-E14; 9-heptadecyl 8-{(2-hydroxyethyl)[6-oxo-6-(undecanyloxy)hexyl]amino}octanoate (SM-102); and (4-hydroxybutyl)azanediyl]bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315).
28. The Lyme disease vaccine of claim 27, wherein the cationic lipid is cKK-E10.
29. The Lyme disease vaccine of any one of claims 22-28, wherein the LNP further comprises a polyethylene glycol (PEG)-conjugated (PEGylated) lipid.
30. The Lyme disease vaccine of claim 29, wherein the PEGylated lipid comprises dimyristoyl-PEG2000 (DMG-PEG2000) or 2-[(polyethylene glycol)-2000]-N,N-ditetradecanoylacetamide (ALC-0159).
31. The Lyme disease vaccine of any one of claims 22-30, wherein the LNP further comprises a cholesterol-based lipid.
32. The Lyme disease vaccine of claim 31 , wherein the cholesterol-based lipid comprises cholesterol.
33. The Lyme disease vaccine of any one of claims 22-32, wherein the LNP further comprises a helper lipid.
34. The Lyme disease vaccine of claim 33, wherein the helper lipid comprises 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) or 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC).
35. The Lyme disease vaccine of any one of claims 22-34, wherein the LNP comprises: A cationic lipid in a molar ratio of 35% to 55%, A polyethylene glycol (PEG) conjugated (PEGylated) lipid at a molar ratio of 0.25% to 2.75%, 20% to 45% by molar ratio of cholesterol-based lipids, and A molar ratio of 5% to 35% of helper lipids, All molar ratios are relative to the total lipid content of the LNP.
36. The Lyme disease vaccine of claim 35, wherein the LNP comprises: The molar ratio is 40% cationic lipid, The molar ratio of PEGylated lipids was 1.5%, 28.5% cholesterol-based lipids, and The molar ratio is 30% of helper lipid.
37. The Lyme disease vaccine of claim 35, wherein the LNP comprises: The molar ratio is 40% cKK-E10, The molar ratio is 1.5% DMG-PEG2000, The molar ratio is 28.5% cholesterol, and The molar ratio is 30% DOPE.
38. The Lyme disease vaccine of any one of claims 21-37, wherein the average diameter of the LNP is 30-200 nm.
39. The Lyme disease vaccine of any one of claims 21-38, wherein the average diameter of the LNP is 80-150 nm.
40. The Lyme disease vaccine of any one of claims 1-39, wherein the mRNA comprises at least one 5' cap, at least one 5' untranslated region (5'UTR), at least one 3' untranslated region (3'UTR) and / or at least one polyadenylation (poly A) sequence.
41. The Lyme disease vaccine of any one of claims 1-40, wherein the mRNA comprises at least one 5' untranslated region (5'UTR), at least one 3' untranslated region (3'UTR), and at least one polyadenylation (poly A) sequence.
42. The Lyme disease vaccine of any one of claims 1-41, wherein the mRNA comprises at least the following structural elements: (i) a 5' cap having the following structure: (ii) a 5' untranslated region (5'UTR) having the nucleic acid sequence of SEQ ID NO: 14; (iii) at least one OspA open reading frame having the nucleic acid sequence of any one of SEQ ID NOs: 16-19; (iv) a 3' untranslated region (3'UTR) having the nucleic acid sequence of SEQ ID NO: 15; and (v) Poly A tail.
43. A Lyme disease vaccine comprising a messenger RNA (mRNA) comprising an open reading frame (ORF) encoding at least one antigenic polypeptide derived from at least one Borrelia bacterium, wherein the mRNA comprises at least the following structural elements: (i) a 5' cap having the following structure: (ii) a 5' untranslated region (5'UTR) having the nucleic acid sequence of SEQ ID NO: 14; (iii) at least one OspA open reading frame having the nucleic acid sequence of any one of SEQ ID NOs: 16-19; (iv) a 3' untranslated region (3'UTR) having the nucleic acid sequence of SEQ ID NO: 15; and (v) poly A tail; Wherein the mRNA is formulated in a lipid nanoparticle (LNP), the lipid nanoparticle comprising: The molar ratio is 40% cKK-E10, The molar ratio is 1.5% DMG-PEG2000, The molar ratio is 28.5% cholesterol, and The molar ratio is 30% DOPE.
44. The Lyme disease vaccine of any one of claims 1-43, for use in eliciting an immune response in a subject.
45. The Lyme disease vaccine of claim 44, wherein the immune response is a humoral immune response.
46. The Lyme disease vaccine of any one of claims 1-45, for use in treating or preventing Lyme disease in a subject in need thereof.
47. A Lyme disease vaccine as described in any one of claims 44-46, wherein the subject has a higher serum concentration of anti-OspA antibodies after administration of the Lyme disease vaccine relative to a subject administered a Lyme disease vaccine comprising an OspA recombinant protein vaccine.
48. The Lyme disease vaccine of any one of claims 44-47, wherein the subject is a mammal.
49. The Lyme disease vaccine of any one of claims 44-48, wherein the subject is a human, dog, cat, llama, cattle, sheep, goat, horse, rodent, mouse, rat, rabbit, monkey, primate or pig, more preferably a human.
Citation Information
Patent Citations
Alkenyl substituted 2,5-piperazinediones, compositions, and uses thereof
US10201618B2
Delivery of mRNA for the augmentation of proteins and enzymes in human genetic diseases
US20110244026A1
Lipid nanoparticle compositions and methods for mRNA delivery
US20140206753A1
Pulmonary delivery of mRNA to non-lung target cells
US20150157565A1
Quantitative assessment for cap efficiency of messenger RNA
US20160032356A1
